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The cellular composition of tumors is highly heterogeneous, involving not only
divergent lineages of transformed cancer cells, but also host cells of the stroma
and immune system. The complicity of protumoral host cells is essential for
conferring malignancy and promoting progression in tumor in a wide range of
solid tissues, including breast, pancreas, and brain. This understanding has led
to the concept of ecological treatment: that is, molecular therapies aimed not
directly at the destruction of cancer cells, but at disrupting interactions between
tumor cells and host cells or the microenvironment, in effect creating a microen-
vironment unfavorable for tumor progression. In order to design effective eco-
logical interventions and predict the course of progression of complex tumors, a
quantitative understanding of the interactions between cellular subpopulations
in tumors is essential. The theoretical branch of ecology has long established
a history of using mathematical modeling to describe and predict the behavior
of heterogeneous populations consisting of myriad interacting individuals each
susceptible to noise in their responses to local stimuli, and complex systems
comprised of different subpopulations engaged in asymmetrical interactions.
We adapt some of these models—specifically, an agent-based self-propelled
particle model and a population dynamics differential equation model—to the
problems of stromal cell-dependent cancer cell migration and growth. From
the former study, I find that paracrine signaling between tumor cells and in-
creases the stability and efficiency of a preexisting tumor cell collective migra-
tion phenotype, rendering the net comigratory behavior more robust against
microenvironmental fluctuations. From the latter study, I find that gliomas de-
pendent upon protumoral tumor-associated macrophages for growth undergo
multi-phasic growth dynamics. I also conclude that macrophage-targeted treat-
ment of such tumors in a linear stage of progression leads to tumor reduction
dependent on the size and composition of the tumor at the time of treatment
initiation, and that tumors exhibiting weak response to such a treatment may
harbor hidden vulnerability to combinatorial therapy. In addition, I infer from
these theoretical studies possible methods of intervening in protumoral ecolog-
ical interactions.
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CHAPTER 1
INTRODUCTION TO THE CANCER ECOSYSTEM
1.1 The multistage clonal sweep theory of cancer and where it
got us
The persistently dominant model of the progression of cancer on the cellular
level has been that of evolution through multistage clonal sweeps [119, 112]. Ac-
cording to this paradigm, cancer is stochastically initiated by genomic alteration
in a single cell of origin, conferring that cell and its descendent clones a selective
advantage over surrounding untransformed, ‘healthy’ cells. This selective ad-
vantage is driven by the acquisition of one or more phenotypic markers of a set
known as the hallmarks of cancer [86]. Such ‘hallmarks’ include evasion of apop-
tosis, unrestricted proliferation, and invasion. The tumorigenic clone would
expand and generate a genomically identical descendant population. From this
clonal background, one offspring cell would stochastically acquire a mutation
conferring a second hallmark of cancer, rendering it more selectively fit than its
peers and forebears. The clones of this cell would outcompete the other cells in
the tumor and sweep through the tumor, replacing all cells in the tumor with
its clones. (It was speculated that there was a sequence by which the hallmarks
of cancer must be acquired, though this sequence was unknown.) This new
population would then form the background for the emergence of the next gen-
eration of cancer cells expressing the third hallmark of cancer, etc., and thus
drive the cancer toward increasing malignancy as the overall cancer cell popu-
lation expanded locally through growth and invasion into surrounding tissue,
and eventually distally through metastasis.
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The multistage clonal sweep theory of cancer was generated and corrob-
orated by, observations of homogenized tumor tissue near the end stages of
the disease, when tumors become clinically detectable. At this stage, tumors
display maximal malignancy and evolutionary fitness. The advent of genomic
sequencing led to the discovery of mutations and copy number alterations dis-
tinguishing cancer tissue from ‘normal’ tissue in the same individual that were
repeatedly observed across different patients of the same disease type. This re-
sulted in a view of cancer in which each cell in a tumor possessed the full set
of phenotypes necessary to drive cancer progression, and these phenotypes, in
turn, were caused by a limited set of genomic alterations. Thus originated the
creation of targeted therapy—the design of molecules that would bind to and in-
hibit the expressed protein products of dysfunctional genes responsible for gen-
erating the hallmarks of cancer in malignant cells. Among the best-known and
most effective examples of such treatments are the treatment of chronic myeloid
leukemia with Gleevec (imatinib) [49, 113] and the treatment of melanoma with
BRAF inhibitors [62].
1.2 Intratumoral heterogeneity and the cancer ecosystem
1.2.1 Heterogeneity in the cancer cell population
Although capable of achieving unprecedented response with few to no side ef-
fects on short time scales, continued effectiveness of most targeted therapies
are eventually stymied by regeneration of the tumor from a non-responsive, or
resistant, subpopulation of cancer cells [63], suggesting the presence or devel-
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opment of intratumoral cellular heterogeneity on the genomic and phenotypic
levels [73].
A direct consequence of phenotypic heterogeneity can be the emergence and
maintenance of a subpopulation of cancer cells that resist treatment and/or pos-
sess the capacity to regenerate the tumor mass through proliferation [137] [53].
Others may include the emergence and maintenance of a metastasis-initiating
subpopulation [90]. In other words, a minority subpopulation of cancer cells
could be responsible for clinically significant events such as metastasis or tu-
mor relapse after treatment, leading to apparent resilience of the tumor even in
situations where the majority of malignant cells have been neutralized by treat-
ment or an inhospitable tumor microenvironment. Less obvious consequences
of phenotypic heterogeneity among the cancer cell population can be the emer-
gence of more complex interactions between phenotypic subpopulations and
eventual construction of a ‘cancer cell society’ [89]: a stably heterogeneous sys-
tem whose dynamics are determined by a complex network of interactions be-
tween subpopulations of cancer cells or stromal/immune cells. The dynamics
of such a society of cells may be determined by cooperative [9] as well as com-
petitive interactions.
1.2.2 Models of cancer cell heterogeneity
Within the literature, there are at least three conceptual models for how func-
tional heterogeneity emerges in the cancer cell population. We introduce them
here as the clonal evolution model, the hierarchical differentiation model, and the
phenotypic switching model. In reality, it is most probable that all three models
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have validity, and that their respective proposed mechanisms operate concur-
rently in any biological cancer cell population.
Clonal evolution
The first is the gene-oriented theory of clonal evolution [79]: random genomic
variation emerges due to factors including the loss of genomic stability in can-
cer cells, sometimes known as the ‘hypermutator’ phenotype [106]. Fitness-
conferring mutations are preserved and amplified through Darwinian selection,
though they may not reach fixation due to clonal interference, cooperation, and
other complex ecological relationships between clonal lineages. Clonal diver-
sity may not emerge purely due to fitness effects: as the tumor expands in size,
it is possible for different clonal lineages to segregate due to genetic drift at the
expanding front. Thus, different spatial regions in a solid tumor may exhibit
different genomic profiles. This phenomenon has been observed in bacterial
cultures [84].
Cancer stem cells
On the other hand, even genetically identical cancer cells can differ in pheno-
type. One proposed mechanism for this variation is the cancer stem cell model.
This model proposes that cancer cells are divided into self-renewing cancer
stem cells (CSCs) and differentiated cells with limited renewal capacity. Because
CSCs are not limited in the number of divisions they may undergo, though they
may comprise a minority of cells in the overall cancer cell population, they may
be able to regenerate the tumor after therapy has depleted the majority of differ-
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entiated cancer cells [52]. Furthermore, because CSCs have unlimited renewal
potential, compared with differentiated cells that are limited in the number of
divisions they may perform, mutations will accumulate in the CSC compart-
ment and propagate to the differentiated cell population.
Phenotypic switching
Phenotypic heterogeneity within a clonal population can also result from in-
trinsic stochastic fluctuations of intracellular regulatory networks. Huang et al
suggested [91] that the complex regulatory networks governing cell behavior
possess a finite number of attractor states, corresponding to cell fates. Intrinsic
thermodynamic fluctuations within this network may drive transition between
phenotypes. In agreement with this conjecture, Gupta et al [82] found that breast
cancer cells stochastically convert between stem-like, luminal, and basal pheno-
types with dynamics that can be fit to a Markov state transition model, and that
each purified phenotypic subpopulation is capable of differentiating to gener-
ate the input distribution of phenotypes in culture. They also found differential
susceptibility of phenotypes for chemotherapy, and predict that cells in a non-
responsive state could regenerate the phenotypic repertoire post-therapy.
Phenotypic heterogeneity can also be driven by microenvironmental condi-
tions [25, 74]. One behavior of cancer cells for which which environmentally-
determined phenotypic differentiation is collective migration [97]. Cells at
the leading edge of migrating cell groups are polarized by the asymmetry of
integrin-mediated contact with the extracellular matrix at the leading pole ver-
sus the cadherin-mediated contact with follower cells at the trailing pole. Coor-
dination between leader and follower cells then leads to collective motion.
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1.2.3 Stromal cells
Intratumoral heterogeneity exists not only in the sense that the cancer cell pop-
ulation is genomically and phenotypically diverse, but in the sense that the tu-
mor microenvironment is populated by non-transformed host tissue and im-
mune cells. Increased resolution of the dissection of cell subpopulations within
tumors has also led to the realization that not all expression of the hallmarks
of cancer is autonomous to normal cells, but may be provided by host cells re-
cruited to the tumor microenvironment [87, 85]. The participation of endothelial
cells is required for neoangiogenesis [20]—the generation of new blood vessels
to irrigate tumors and supply them with oxygen and nutrients—and the in-
travasation and extravasation processes at the beginning and end, respectively,
of the metastatic cascade [165]. Immune cells perform a notably significant and
diverse set of functions: for example, macrophages [120, 109, 162, 93, 123] me-
diate cancer growth, metastasis, and resistance to therapy. Activated tumor-
associated fibroblasts can also drive the invasion of epithelial cancers [21, 70].
Though seemingly aberrant, many of the protumoral activities of host cells
can be interpreted as co-opted or misdirected processes crucial for regeneration
or development [45, 65]. This concept has also been expressed in the conceptu-
alization of tumors as ‘wounds that do not heal’ [57]. Such mechanisms have
evolved over the history of multicellular life on Earth to maintain robust func-
tion and integrity in healthy tissues in the face of unpredictable environmental
perturbations [1]; naturally, they often resist attempts to disrupt or manipu-
late them through artificial means. To further complicate the issue, biological
systems evolved for robustness often follow different ‘design patterns’ than ar-
tificially engineered ones [167], making the task of design effective means of
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manipulating or disrupting such systems difficult.
Feedback in tumor-microenvironment interactions leads to the co-evolution
of cancer cells and their environment [131]. As with many dynamical systems
involving feedback interactions, the output of tumor-microenvironment inter-
actions can be chaotic and unpredictable, as can consequences of attempts to
perturb the system with conventional or targeted treatments. Thus, data taken
from fixed tissue without temporal resolution will give limited insight as to how
these complex interactions collectively influence disease progression.
1.3 Challenges of experimental studies of cancer ecology
Experimental dissections of the complex cancer ecosystem are necessarily lim-
ited in scope, resolution, or both. Large-scale sequencing efforts provide a com-
prehensive view of the genomic and transcriptomic state of the tumor, but the
collection of such data via biopsy is typically invasive for solid tumors, and thus
cannot provide high (if any) resolution in the temporal domain. Translating se-
quencing data to phenotypes relevant to the tumor population dynamics still
faces difficulties.
Single-cell real-time imaging techniques can observe the morphology and
behaviors of cells as well as the spatial organization of solid tumors directly.
Intravital fluorescence microscopy allows in vivo monitoring of cell-cell inter-
actions, and has been used to image key events in cancer invasion such as
collective migration and extravasation to a metastatic site [2]. However, this
technique is also invasive, with sustainable experimental duration measured in
days. This may fail to capture longer-term dynamics of the tumor system, espe-
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cially evolutionary events.
In vitro experiments offer benefits such as the capacity to track single cells
and quantitation of signaling molecules. Microfluidic platforms are useful for
imaging simple cell migration behaviors or cell-cell signaling [33]. Such assays
are particularly informative in measuring the response of cells to diffusion-
limited chemical signals. On the other hand, such experiments often involve
cultured cell lines, which are demonstrably different from primary cells genet-
ically and epigenetically [146]. Furthermore, as in vitro assays are a synthetic
system—that is, they do not contain elements that have not been explicitly in-
serted by the experimenter—it may be difficult to capture the full scope of in
vivo tumor complexity in an in vitro system.
Finally, with all fluorescence-dependent microscopy techniques, the number
of microenvironmental elements that may be captured in a single experiment is
constrained by the feasibility of genetic manipulation and the number of wave-
lengths that may be simultaneously measured. These techniques are useful for
quantifying the activity of specific molecular pathways with a few known com-
ponents. However, multicellular dynamics on larger time- and length-scales
require integration of the outputs from vast numbers of molecular mechanisms;
it is almost certain that the full long-term dynamics of a tumor rely on more
molecular components than can be quantitatively imaged via fluorescence mi-
croscopy in a single assay.
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CHAPTER 2
THE ROLE OF MATHEMATICAL MODELING IN CANCER ECOLOGY
2.1 An argument of granularity
Given the difficulties of experimentally capturing the full dynamic and struc-
tural complexity of tumors, it is reasonable to turn to mathematical modeling.
As experiments on complex cancer behavior inevitably face an exchange of res-
olution for scope or vice versa, so do mathematical modeling of the same sys-
tems face a similar tradeoff of insight for complexity. To use physical terms,
there is an inverse problem in mathematically modeling cancer progression and
treatment [34]: the phenomena of interest are collective and large-scale (can-
cer growth, treatment, patient health), while the causal mechanisms are specific
and small-scale (gene expression, cell signaling, molecular binding). Though
cancer (and all complex biological systems) displays relevant behavior at all
time- and length-scales—from molecular binding to the cell cycle to the devel-
opment of collective tissues and neoplasms—often the modeling approach will
have to be tailored to the specific scale of the phenomenon or phenomena of
interest, which might be called the ’top’ scale. In cancer biology, one is often
also interested in the next-finer grained length scale where the driving mech-
anisms driving the phenomenon of interest occur, which might be called the
‘bottom’ scale, as this is the level at which pharmaceutical interventions may be
targeted. In terms of the ecology and evolution of cancer, the relevant top scale
is the dynamics of population size and composition; the finer-grained bottom
scale should be the phenotypic cell-cell interactions. This latter scale is one step
removed from the chemical kinetics of signaling pathways and is arguably the
9
appropriate bottom length scale for modeling collective cell behavior, given the
variability of molecular mechanisms between and within tumors that drive sim-
ilar large-scale behaviors of proliferation, invasion, and adaptation. This allows
modeling the emergence of complex behavior while keeping phase space to a
manageable size and increasing the generalizability of any conclusions.
The fields of statistical physics [147] and ecology [16] have long since real-
ized the importance of the inverse problem in understanding the dynamics of
complex systems constructed from large numbers of interrelated components.
Theoretical methods from these fields have found applied use in fields such as
sociology [127] and potentially may be of aid for solving problems in cancer bi-
ology. Below, I describe two super-classes of mathematical models in ecology
that have found applications in cancer: a dynamical modeling paradigm and a
collective modeling paradigm, and my extensions to them resulting in the stud-
ies presented in Chapters 3 and 4.
2.2 Dynamical models
Dynamical modeling of tumor growth has many precedents. The earliest math-
ematical models of tumor growth were constructed on the basis of describing
the dynamics of the tumor volume [19, 36, 118]. As the tumor volume is a
system-level observable, these models can be thought of as a ‘top-down’ ap-
proach. While useful in that they condense the phase space of tumor growth
kinetics down to often just a few parameters, classical dynamics models fail to
capture temporal fluctuations and spatial structure that may have a defining im-
pact on the course of disease or diagnosis. They also typically do not account for
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heterogeneity of cell populations in the tumor. Finally, even when classical mod-
els are able to reproduce the growth dynamics of real tumors, these results are
often mostly descriptive, as they do not relate the bulk dynamics to parameters
of cellular and molecular interactions. Thus, their capacity for inspiring novel
therapeutic strategies—which usually take the form of meticulously designed
and screened molecules—is inherently limited. For the purpose of studying tu-
mor ecosystems, a mathematical model of greater detail may be desired.
An incremental generalization of dynamical models of bulk tumor growth
to heterogenous cell populations is to regard it as a network of interacting sub-
populations that are individually homogeneous. This can be thought of as a
‘middle-up’ approach. A classical example of such a model is the Lotka-Volterra
model [125]. This model describes a system by the abundances of its component
subpopulations, and the dynamics of the system are determined by nonlinear
ordinary differential equations specifying the rates of change of each subpopu-
lation as a function of interactions between subpopulations, or between a sub-
population and a global resource variable. The Lotka-Volterra equations can
be applied to examples such as predator-prey relations or competition between
species that rely on a common nutrient source.
The Lotka-Volterra model is conceptually related to models based on evolu-
tionary game theory (EGT). In EGT models, dynamics are determined by spec-
ifying the ‘payoff’ of interactions between ‘players,’ interpretable as subpopu-
lations. Population dynamics are then calculated from the frequencies of each
interaction and their respective frequencies and payoffs of each interaction. EGT
models are currently finding use in investigating events in early tumorigenesis,
including how an initial minority of cancerous cells can invade a population of
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normal tissue cells in homeostasis [13].
Potential uses of the Lotka-Volterra and related models in investigating cell
population dynamics in cancer include competition between normal and can-
cerous cells for limited microenvironmental resources such as oxygen, glucose,
or cytokines [25, 77]. Another application would be to explore possible out-
comes of interactions between cancer cells and the systemic immune response
[160, 54]. Tumor-infiltrating immune cells such as macrophages and T-cells have
been hypothesized play both anti- and pro-tumoral roles [116, 109]; the net out-
come of immune infiltration of tumors may depend not only on the plasticity of
intracellular regulatory networks but on the dynamical balance between anti-
and pro-tumoral immune subtypes. I use a Volterra-like model to explore this
problem in Chapter 4.
2.3 Collective models
On the level of subpopulations, the Lotka-Volterra model is a mean-field ap-
proximation; within populations, individuals encountering different environ-
mental conditions, or simply experiencing different stochastic fluctuations due
to thermodynamic factors, may display different phenotype and behavior. The
population output integrates, through interactions between individuals, the in-
dividually noisy stimuli-response calculations. These models fall under the gen-
eral category of agent-based models (ABM)[170], in which collectives of inter-
acting individuals or agents (e.g. cells) are simulated to observe the resultant col-
lective behavior. These models, constituting a ‘bottom up’ simulation approach,
have an additional advantage of being integrable with a continuum representa-
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tion of diffusible chemical gradients, for example of cytokines or glucose. Such
integrated models are sometimes referred to as hybrid discrete-continuum (HDC)
models [4, 44]. Between the discrete-space representation of cells and their spa-
tial organization, and the continuum representation of chemical species, HDC
models have the potential to simulate the aggregate output of a multitude of
regulatory mechanisms and interactions.
ABMs are useful for exploring the effect of spatial structure on population
dynamics. In microbial and tissue systems, diffusive substances such as nu-
trients and growth factors often have a decisive effect on population dynamics.
The spatial distribution of resources and individuals thus determine the dynam-
ics of the ecosystem. For instance, spatial structure can explain the emergence
and maintenance of public-goods cooperative behavior in evolving populations
if cooperative individuals aggregate and the public good is spatially limited
[158]. This is readily demonstrated in agent-based spatial simulations for the ex-
ample of bacterial colonies [117]. Using a variant of the bacterial model, it is also
possible to show the emergence of a cooperative subclone in a two-dimensional
spherical tumor (Fig. 2.1). Conversely, the emergence of spatial structure can
be evidence of interspecific interactions [25]. The presence of intricate spatial
structure and nonuniform distribution of cell types within tumors [76, 168] may
point to the dominance of interspecific effects within tumor cell populations.
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Collective behavior in tumor growth
Abstract
Many hallmarks of cancer, such as angiogenesis or the secretion of 
signals for self-sufficient growth and apoptosis evasion, can be seen as 
cooperative behaviors. These traits are performed by individual tumor 
cells at a cost to their own proliferative efficiency, but can benefit many 
other cells in the within the tumor, a form of “public good” cooperation. 
In evolutionary theory, cooperative traits are vulnerable to invasion by 
"cheaters"--individuals which benefit from a “public good” but who do 
not contribute to its production. However, the evolution of such traits is 
necessary for tumor growth and invasion. We use an agent-based 
computational model with physically-modeled diffusion-reaction to 
investigate the evolution of cooperative behavior in solid tumors. The 
model predicts that, even when costs of cooperation are high, 
spontaneous cooperative mutants can get established in a tumor if they 
arise in a favorable microenvironment and proliferate beyond a critical 
number of inter-cooperating cells. We are currently applying the model to 
positive feedback interactions between tumor cells and macrophages in 
the tumor microenvironment. 
 In addition, drawing inspiration from concepts in ecology and 
statistical mechanics, we are extending the model to simulate and analyze 
collective migratory behavior in tumor cells, in response to 
microenvironmental cues and cell-cell interactions. The model predicts 
that directional correlation between cells in a migrating cluster increases 
the accuracy of chemotaxis on the population level, even when the 
gradient sensitivity of the individual cell is low relative to noise. 
Ultimately, we aim to use the model to reproduce invasive dynamics seen 
in vivo and in vitro, and explore the parameter combinations that give rise 
to the spatial patterns of tumors seen in experiments.
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Figure 2.1: The simulation is initiated with one non-cooperative (‘cheater’) tu-
mor cell at the center of the simulation space. Growth signal is initially uni-
formly distributed throughout the space, but gradients emerge as the signal is
consumed by growing cells. Stochastic emergence of a cooperative subtype,
which expresses the growth signal at a cost to its own growth, at the edge of
the expanding tumor leads to a locally high concentration of growth signal and
overall acceleration of cell growth. The emergent spatial structure—aggregation
of cooperators and consequent segregation of public goods—stabilizes the co-
operative subpopulation.
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2.3.1 Collective migration models
One problem in which agent-based models have proven useful in studying is
the phenomenon of collective motion. Biological organisms at all scales rang-
ing from bacteria to mammals exhibit coordinate motion between individuals
in a group, and similar phenomena can be observed even in inorganic systems
[157]. Much of the work done in this field—investigating how collective pat-
terns of motion arise from signaling or mechanical interactions between mov-
ing individuals—has been performed using a special instance of agent-based
models known as the self-propelled particle (SPP) model [156]. Simulations us-
ing the basic SPP model show that a system of moving individuals can exhibit
discontinuous changes in qualitative behavior—better known as a phase transi-
tion—as the parameters governing the response of individual particles and the
density of particles are continuously varied. Extensions of this model have been
used to investigate biological questions such as cell sorting during development
[17, 11].
These existing studies have been primarily inspired by theoretical physics
and applied to problems in developmental biology and microbiology, with a
focus on critical phenomena—that is, qualitative changes of behavior result-
ing from fine tuning of parameters within a narrow range of values. In cancer
biology, collective migration often emerges as a consequence between pheno-
typically distinct cells originating from separate lineages of differentiation. In
Chapter 3 I present an application of this model to the emergence of collective
comigration from interspecific signaling between cancer cells and stromal cells
such as tumor-associated macrophages.
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2.4 Prior modeling studies
Recently, the primary approach to mathematical modeling the cancer ecosystem
has been a mechanistic or quasi-mechanistic focus on integrating individually-
known signaling pathways in an attempt to comprehensively simulate the ag-
gregate impact of many specific molecular species, or categories of molecules
and mechanisms, on tumor progression. These efforts seem to have emerged as
a attempt to reconcile the increasingly-overwhelming body of The parameters
of these models usually correspond to kinetic rate parameters of specific bio-
chemical signaling pathways and cell mechanisms inferred either from isolated
measurements of signaling molecules in controlled cell-biological experiments
[5], or literature reporting the same. Such models are often implemented in spa-
tially structured simulations; in this form, they can serve as a kind of augmented
in vitro experiment, serving as an alternative to spatially-unstructured conven-
tional cell line experiments. One prominent example of such a model is the hy-
brid discrete-continuum (HDC) model developed by Anderson et al [6]. In this
study, the authors observed that a harsh simulated tumor microenvironment
promotes the evolution of invasive tumor cell clones, while a mild microenvi-
ronment enabled less invasive clones to persist and suppress the emergence of
invasive cells through clonal competition.
Integrative mechanistic models can also be conceived as mean-field, differ-
ential equation models. In [162], the authors implemented a glioma model of 5
tumor and stromal cell types, 15 cytokines, and 69 signaling pathways, and ob-
served that the simulated tumor developed in dynamically and compositionally
distinct pre-tumoral, expanding, and saturated stages. They further discover
that treatment depleting microglia is effective for treating such tumors in the
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early stages, but in the late stages cytokine inhibition is required.
These studies show the potential of integrative, mechanistic or quasi-
mechanistic approaches to modeling cell-cell and cell-microenvironment inter-
actions in cancer can predict emergent properties of the tumor that would be
challenging to experimentally obtain. In addition, by grounding the model in
detailed molecular and mechanistic knowledge, such models can propose novel
therapeutics.
The major challenge with mechanistic and quasi-mechanistic modeling stud-
ies is that the complexity of the model increases rapidly as the number of sig-
naling mechanisms represented increases, often making numerical simulation
the only tractable analysis of the model. It is difficult to parameterize such a
complex model. Often reference to literature or experiments measuring stimuli-
response cell dynamics under simplified culture systems, for example, will be
required. However, it cannot always be guaranteed that such dynamics will
remain quantitatively consistent when combined with other mechanisms in a
complex experimental or simulated environment. Additionally, the significance
of any interaction or parameter then becomes difficult to disentangle from the
context of every other interaction and parameter in the system, and in cases
where a specific effective perturbation of the system cannot be readily identi-
fied from simulation outputs, extracting useful insight from the model becomes
a challenge.
Phenomenological modeling has been less prominent in recent years, due
to their abstraction and the dominance of molecular biology. One remark-
able exception can be found in a study by Leder et al [103]. In summary,
the authors constructed a simple population dynamics model integrating phe-
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notypic switching between radiation-sensitive and -resistant states in PDGF-
driven glioma cells. The model was parameterized from MRI experiments and
literature, and a Monte Carlo optimization algorithm was used to propose a
radiation dosing schedule to minimize the number of residual tumor cells two
weeks after conclusion of treatment. The resulting novel treatment strategy was
tested in a mouse model and found to provide improved response compared to
the standard clinical dosing schedule. This study is a prominent recent exam-
ple of how non-mechanistic models, working in correspondence with experi-
mentation towards a well-defined optimization endpoint, can yield biologically
significant results.
On the other hand, this type of modeling approach amounts to a parameter
optimization problem, one of peculiar clinical relevance, and is tightly bound
with a specific set of conventional biological experiments. Therefore, the gener-
ality of the modeling results, or their applicability to other biological systems,
may be difficult to know a priori. More abstract, parameter-independent ap-
proaches may be preferable if the goal is rather to illuminate the general princi-
ples of multicellular dynamics in tumors.
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CHAPTER 3
TUMOUR-STROMAL INTERACTIONS GENERATE EMERGENT
PERSISTENCE IN COLLECTIVE CANCER CELL MIGRATION
This chapter has been previously published as [29].
3.1 Abstract
Cancer cell collective migration is a complex behaviour leading to the invasion
of cancer cells into surrounding tissue, often with the aid of stromal cells in
the microenvironment, such as macrophages or fibroblasts. Although tumour-
tumour and tumour-stromal intercellular signaling have been shown to con-
tribute to cancer cell migration, we lack a fundamental theoretical understand-
ing of how aggressive invasion emerges from the synergy between these mech-
anisms. I use a computational self-propelled particle model to simulate inter-
cellular interactions between co-migrating tumour and stromal cells and study
the emergence of collective movement. I find that tumour-stromal interaction
increases the cohesion and persistence of migrating mixed tumour-stromal cell
clusters in a noisy and unbounded environment, leading to increased cell cluster
size and distance migrated by cancer cells. Although environmental constraints,
such as vasculature or extracellular matrix, influence cancer migration in vivo,
our model shows that attractive cell-cell interactions are sufficient to generate
cohesive and persistent movement. From our results, I conclude that inhibi-
tion of tumour-stromal intercellular signaling may present a viable therapeutic
target for disrupting collective cancer cell migration.
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3.2 Introduction
One of the most harmful features that tumour cells acquire is the ability to mi-
grate and invade surrounding tissues, leading to deadly systemic metastases
[64]. This has fueled an active research programme to understand cancer cell
migration and invasion from experimental and theoretical points of view. Novel
techniques for direct visualization of tumour invasion in vivo [38] have revealed
that cancer cells frequently migrate as groups of closely interacting cells [67].
The phenomenon of collective cell migration also emerges in a broad range
of ‘normal’ physiological conditions ranging from embryonic development to
wound-healing [139]. However, we still lack a complete and thorough under-
standing of how individual cells coordinate to migrate collectively.
Ecological models may be useful in understanding cancer collective migra-
tion. Collective migration is observed in biological systems of many disparate
length scales, ranging from bird flocks [157, 122, 28] to bacterial swarms [41, 42].
It is an emergent phenomenon and a universality class, in which the large- scale
properties of the collective result from the activities of individuals, but are to
some extent independent of the specific behaviour of individuals [152, 95]. Sim-
ilarly, in cell biology, collective migration of groups of closely interacting cells
has been implicated in such behaviours as organ morphogenesis during em-
bryonic development or vascularization [139, 26, 65, 149, 128] and, the main
motivation for our study, cell invasion during cancer progression [48, 65].
One of the most successful theoretical approaches to study the emergence of
collective migration from simple interactions between moving individuals are a
class of models called self-propelled particles (SPPs). In the classic SPP model
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[156] an individual moving at a fixed speed interacts with its neighbours by
aligning itself with the average direction of all individuals within a given radius.
These simple rules for local interaction give rise to emergent global properties,
such as a phase transition from disordered, or individual, motion to ordered, or
collective, motion with a decreasing level of noise in the interaction. This model
and derivations of it have been applied to numerous problems in collective mi-
gration by using the individual particle to represent real-world individuals in
collectives, such as an animal in a flock [40, 138], micro-organisms in a colony
[18] or a cell in a tissue [94, 150].
Experiments in which a homogeneous cell population displays collective mi-
gration in the absence of other cell types or external signals [27, 66, 88, 150] are
compatible with the original SPP model. However, migratory cancer cells in-
teract not only with each other but also with stromal cells. For example, stro-
mal cells such as macrophages [93, 134] and fibroblasts [70] are known to assist
cancer cell migration through secretion of migration-stimulating cytokines and
proteinases that remodel and create permissive tracks in the extracellular ma-
trix [64, 140]. Thus, the application of the SPP model to cancer is complicated
because cell migration in tumours requires synergy between diverse cell types
[37, 78, 140]. The SPP paradigm has been used before to investigate cell sort-
ing in development and regeneration [11, 17]. However, application of the SPP
to investigating migration emerging from heterotypic and non-reciprocal inter-
actions between distinct classes of motile cells has been limited, though some
examples exist [17].
Here, I explore what are the consequences of implementing experimentally
inspired modifications to the original SPP model. More specifically, I inves-
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tigate what are the consequences of the presence of a small subpopulation—
representing stromal cells—with a distinct behaviour. Thus, I extend the Vicsek
SPP algorithm [156] to introduce an additional particle type representing stro-
mal cells. Tumour-associated macrophages are one of the most abundant and
well-studied stromal cell types within solid tumours [134]. These macrophages
are known to attract cancer cells, and this interaction is crucial for tumour inva-
siveness in vivo [140, 164, 166]. Based on these observations, I add a specific non-
reciprocal attraction rule compelling cells of one type (tumour) towards nearby
cells of the second type (stromal). This attraction has a relatively longer range
of action, i.e. can occur between non-adjacent cells. I use our expanded model
(hereafter referred to as the cancer-stromal model) to explore cell displacement
and cell cluster size as metrics for quantifying the impact of stromal cells on
collective cancer cell migration. Our simulations suggest that stromal cells can
have profound implications for large-scale cancer cell collective migratory pat-
terns and, consequently, for tumour aggressiveness.
It is important to stress that, although our initial motivation is to model at-
tractive macrophage-tumour interactions described experimentally [140, 164,
166], our model is simplified and neglects other aspects of cancermacrophage
interaction such as angiogenesis promotion [108, 126] and modulation of the
inflammatory response [39]. We also note that our simulations occur in an un-
structured space. In other words, the results of our model should be interpreted
as the intercellular signaling component of collective cell migration, removing
the effects of tumor microenvironmental structure. In summary, the model is
general and can be extended to any other attractive stromal cell. Expansions of
model features can be made to account for noncellular elements of the tumor
microenvironment.
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3.3 Results
3.3.1 Extending self-propelled particles to model a tumour-
stromal interaction
We use the homogeneous population of SPPs with one simple alignment rule
as described in the original SPP model [156] as a starting point to model mi-
grating tumour cells. To this population, we introduce a minority population
of a second type of SPP, representing stromal cells. Cells of both kinds, tumour
or stromal, align non-specifically to the mean polarization of cells in the neigh-
bourhood. In addition, we add an attractive tumour-stromal interaction. This
interaction is assumed to be type-specific and asymmetrical, that is, tumour cells
are attracted to nearby stromal cells, but not vice versa (Fig. 3.1A). The angle of
polarization θ of each cancer cell i is thus recalculated at each iteration:
θit + 1 = 〈θ(t)〉ral + ats〈arg(~ri j)〉rts + ∆θ (3.1)
where θ(t)ral is the mean angle of polarization of all cells within distance ral
of the focal tumour cell i; ats is the strength of the attractive tumour-stromal
interaction relative to cell-cell alignment; arg(ri j) is the mean angle of vectors
from the centre of focal tumour cell i to all stromal cells j within distance rts
of cell i; and ∆θ is a random angle on the interval [−η, η], representing noise.
The polarization calculation for stromal cells lacks the second term, and thus is
identical to the migration rule in [17],
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Figure 3.1: A) Cell-cell interactions in the Cancer-Stromal Model of self-
propelled particles. Cells move at fixed speed. Stromal cells align nonspecif-
ically to local mean direction of motion. Tumor cells align nonspecifically in
addition to moving towards any nearby stromal cells. p represents the polar-
ity of cell motion. B) Order parameter quantifies the extent of cell polarization.
When the global order parameter is ≈ 0, cells are randomly polarized. When
the global order parameter is ≈ 1, cells are polarized in the same direction. C) In
a system with no tumor-stromal attraction (ats = 0; i.e. all cells behave as tumor
cells) with low noise and cyclic boundary conditions, in the infinite-time limit,
the global order parameter approaches 1: almost all cells eventually group into
a single coherent cluster, where individual polarizations deviate little from the
mean polarization of the cluster. In a high-noise system, the global order pa-
rameter approaches 0, and the cells are spread throughout the available space
with no discernible clustering.
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θi(t + 1) = 〈θ(t)〉ral + ∆θ (3.2)
All length scales and cell speeds in the model are normalized as previously
[156]: that is, the range of cell-cell alignment, ral, equals 1. Local interaction
mechanisms such as cell- cell adhesion and shear viscosity at high cell density
[151] can account for this short-range alignment.
Conversely, we assume that the possible mechanisms for tumour-stromal
interaction, such as paracrine signaling through diffusible molecules [140, 164],
chemotactic motility from cancer cells towards stromal cells or forms of long-
range alignment via adhesion to common collagen fibres in the extracellular
matrix [64, 140], have greater effective range than those contributing to cell-
cell alignment adhesion to common collagen fibres in the matrix [64], and set
rts = 2. Interaction and noise strengths are normalized to the cell-cell alignment
strength; that is, cell-cell alignment strength equals 1. The noise amplitude, η,
varied from 0 ≤ η ≤ 5, which is the range in which the ordereddisordered phase
transition was observed previously [156], and the interaction strength, ats, var-
ied from 0 ≤ ats ≤ 2.
All simulations were performed in two dimensions, replicating the cell den-
sity and boundary conditions, again as used previously [156]. We used a ratio
of 4000 simulated tumour cells and 40 simulated stromal cells. With ats = 0, the
stromal cells effectively behave identically to the tumour cells and the model
should be equivalent to the original SPP. Our cancer-stromal model, when its
additional parameters are set to 0, thus reproduces the behaviour previously
observed in the original SPP study [156]. Simulation parameters are summa-
rized in Table 3.1.
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parameter value rationale
cell migration speed 0.03 as in [156]
size of simulation
space
31.6 × 31.6 as in [156]
range of cell-cell
alignment
1 as in [156]
strength of cell-cell
alignment
1 as in [156]
noise 0 ≤ η ≤ 5 as in [156]
number of cancer
cells
4000 as in [156]
number of stromal
cells
40 See 3.3.2
range of tumor-
stromal attraction
rt s = 2 See 3.3.2
strength of tumor-
stromal attraction
at s = [0, 0.2, 0.4, 0.6, 0.8, 1.0, 2.0] See 3.3.2
Table 3.1: Parameters used in the tumor-stromal model. Parameters not in the
original SPP model [156] are highlighted.
3.3.2 Rationale for values of new parameters
• Number of stromal cells. We initially performed simulations with a small
minority of stromal cells (1 in 100) to perturb the system minimally.
When this small subpopulation proved to have significant effect on the
population-level collective migration performance, we used this stromal
ratio for all simulations. From fluorescent cross-section data in e.g. [133],
one can infer the bulk relative abundance of macrophages in late-stage
solid tumors (glioma in this case) as being approximately 10-20%. How-
ever, this does not distinguish between macrophage phenotypes, or mi-
croenvironmental variability affecting the role individual macrophages
play in interactions with the local tumor cell subpopulations. It is impor-
tant to note that in unbounded simulations, because of the heterogeneity
generated by cell dispersion, effective stromal cell ratio per interconnected
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cell cluster varies greatly (from 0% to 100%), and thus the global stromal
cell ratio does not have direct biological translation.
• Range of tumor-stromal attraction (rts). We assume that cell-cell alignment
occurs through either direct contact-based E-cadherin-mediated coupling
through adherens junctions or mechanical shearing. The normalized
alignment range (ral ≡ 1) can thus be thought of as the radius of a single
cell. The tumor-stromal interactions are assumed to represent paracrine
signals, such as the well-documented EGF/CSF-1 paracrine signaling loop
between breast cancer cells and tumor-associated macrophages [78]. As
such, they are expected to have a longer effective range, but still within
the same order of magnitude in terms of cell lengths, as contact-mediated
interactions [15]. An effective interaction length of rts = 2 satisfies this
constraint. Though we did not experiment with different values of rts,
one can speculate that this will have qualitatively a similar large-scale ef-
fect as reducing the noise, and thus increasing the effective distance by
which the tumor-stromal interaction signal can be propagated by interac-
tions between cancer cells. That said, experimenting with changes in rts,
or performing dimensional reduction to generate a model that is indepen-
dent of the specific value of rts, could be an interesting direction for future
research.
• Strength of tumor-stromal attraction (ats). The strength of the tumor-stromal
attraction is defined relative to the strength of cell-cell alignment with ats
as the scaling factor. We experimented with a range of values for ats, rang-
ing from ‘control’ simulations with no tumor-stromal attraction (ats = 0)
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to attraction twice as strong as alignment (ats = 2). There was no signifi-
cant variation in the population-level behavior, and for simplicity we fixed
ats = 1 for subsequent simulations.
3.3.3 Tumour-stromal interaction enhances collective migra-
tion in noisy environments
We first evaluated whether our model performed behaved consistently by cal-
culating the global order parameter, a key parameter in the original SPP model
[156]. Briefly, the order parameter quantifies the average direction of particles,
which we then compared at the pseudo-steady state (10000 iterations) with the
results in the original study. As expected, a global order parameter of ≈ 0
indicates a disordered system with cells randomly polarized and distributed
throughout the simulation space, while a global order parameter of ≈ 1 indi-
cates a system where all the cells are roughly aligned and migrating as a single
coherent cluster (Fig. 3.1B-C). A phase transition from ordered to disordered
motion occurred as η increases. These observations confirmed that our SPP im-
plementation corresponded to the original model [156].
We then considered the effect of tumor-stromal attraction on the order of
motion by setting ats to positive values. Simulations with ats > 0 showed notable
deviations from the original SPP model [156]. We observed high variability in
global order at the end of the simulation runs, but with opposite trends for low
and high noise. The global order decreased compared to ats = 0 for low values
of η(η < 2.5), and increased for high values of η (η ≥ 3, Fig. 3.2). End-simulation
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Figure 3.2: Global order parameter as a function of noise in a system with cyclic
boundary conditions. Under a fixed value of ats, as η is increased, the system
exhibits a phase transition from an ordered (global order parameter ≈ 1) to dis-
ordered (global order parameter ≈ 0). When ats = 0, the phase transition occurs
as in ref. 14. When ats = 1.0, global order is decreased for low values of eta,
but increased for high values of eta compared to the ats = 0 system. Aster-
isks indicate significant difference between the ats = 1.0 and ats = 0 simulations
(p < 0.001).
global order did not noticeably vary between simulations with different positive
values of ats and the same value of η (not shown). The effect of changing cell
density simultaneously with noise on the phase diagram of the order parameter
is shown in Fig. 3.3.
These results demonstrate that a simple extension to the original SPP can
produce a significant change in the predicted pattern of collective migration
and may have important implications for cancer. Specifically, the results suggest
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Figure 3.3: A) Phase diagram of the median order parameter in the space of
density vs. noise for ats = 0. Asterisks (*) represent data points (5 replicates
each); colors are filled using bilinear interpolation. B) Same as A), for ats = 1. C)
Ratio of values in B) to values in A). This shows that the positive effect of tumor-
stromal interaction on the order can mainly be seen in the regime of medium to
high noise, with the critical noise threshold increasing with cell density. No-
tably, the effect is most observable within the range of densities used in [156].
that tumor-stromal interaction can stabilize cancer collective migration in noisy
systems.
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3.3.4 The effect of stromal stabilization is stronger in expand-
ing tumours
Our model so far, like the original SPP model, assumes cyclic boundary con-
ditions [156], which confine the particles to a space of torus-like geometry and
unrealistically small volume. However, cancer invasion in vivo drives cancer
progression on time and length scales much larger than those of individual cell
migration or even intercellular signaling within small groups of cells [5]. To
extrapolate collective co-migration of cancer and stromal cells to larger length
scales and longer simulation times, we implemented a second extension in our
model, now using an unbounded system where cell migration is essentially un-
limited by spatial constraints (Fig. 3.4A).
We carried out simulations with the unbounded system for a range of inter-
action strength and noise levels and we calculated the global order parameter
after 10000 time steps. As expected, with no tumor-stromal interaction (ats = 0),
the global order decreases towards end of simulation for all levels of noise (Fig.
4.3B). This occurs because in unbounded systems, the decoherent effect of noise
in each cell cluster is cumulative, and unlikely to be cancelled by encounters
with other cell clusters; thus, the ability of the system to sustain large coher-
ent clusters over long time spans is decreased. Adding tumor-stromal inter-
action uniformly increases the end-simulation global order for all noise levels,
implying that tumor-stromal interaction has much greater impact on the coher-
ence of migrating cancer cell groups when the available space is large. Tumor-
stromal interaction delays the disintegration of coherent migrating clusters, and
increases the end-simulation global order (Fig. 3.4B).
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Figure 3.4: Comparison of a system with cyclic boundary conditions to an
unbounded system. Squares indicate areas of inoculation. In a system with
cyclic boundary conditions, cells leaving the area of inoculation will re-enter
the area at the diametrically opposite point, maintaining its polarization. In
an unbounded system, the cell is not spatially constrained and may leave the
area of inoculation. B) Global order parameter as a function of noise in an un-
bounded system. The order of the system decreases rapidly as eta increases.
When ats = 1.0, the order increases for all positive values of eta compared to
simulations where ats = 0. Asterisks indicate significant difference between the
ats = 1.0 and ats = 0 simulations (p < 0.001).
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In addition to calculating the order parameter, we also examined the dis-
tance migrated by cancer cells as a measure of cancer cell invasiveness. For
simulations without tumor-stromal interaction where noise is moderate to high,
the mean displacement rapidly increases initially but starts to level off within
the simulation time (Fig. 4.4A). In contrast, in simulations with tumor-stromal
interaction, the mean displacement increases steadily (linearly) throughout the
duration of the simulation; this increase is seen to saturate within the simulation
time only when noise levels are high (Fig. 3.5A). Consequently, for all positive
values of η tested, tumor-stromal interaction increased the mean distance mi-
grated by cancer cells (Fig. 3.5B). We conclude that tumor-stromal interaction
increases the persistence and ultimately the performance of collective cancer cell
migration, as measured by distance travelled.
We also considered the effect of tumor-stromal interaction on the size of col-
lectively migrating cell clusters, as measured by the number of cells in the clus-
ters. Clusters are defined as groups of cells within the same interaction net-
work, i.e. cells interacting directly or indirectly via other cells. We determined
the presence of cell-cell interactions by thresholding the center-center distance
of each pair of cells with the appropriate interaction range (1 for a pair of tu-
mor cells or a pair of stromal cells, 2 for a heterogeneous pair of 1 stromal cell
and 1 tumor cell) and sorted the cells into clusters using the well established
equivalence class sorting algorithm [132]. Stromal cells were included in the
statistics for their respective clusters; however, as they constituted 1% of the
total population, we assumed they did not significantly affect the overall statis-
tics. Cells not in contact with another cell were interpreted as clusters of size
1. At low levels of noise, tumor-stromal interaction increased the global mean
size of collectively migrating cell clusters compared to the control simulations.
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Figure 3.5: A) Time course of mean displacement of cells in the system. Dashed
lines indicate standard deviation across 5 replicates. The mean cell displacement
at end of simulation is increased for ats = 1.0 when compared to ats = 0. In
the ats = 0 simulations, the rate of displacement increase decreases over time,
whereas the effect is not observable in the ats = 1.0 simulations. B) Persistence
over time of the same simulation sets. The decay of persistence over larger time
scale is more gradual for ats = 1.0. C) Mean persistence over the time scale
of the simulation as a function of noise. The mean persistence is increased for
ats = 1.0 compared to ats = 0 for all values of η > 0 tested. D) Mean cluster size at
simulation end as a function of noise. The mean cluster size is increased for ats =
1.0 at low values of noise. At high levels of noise, tumor-stromal interaction
decreases the mean cluster size, reflecting the dissolution of the cell population
into small clusters.
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However, this trend reversed as η was increased above approximately 2.5, and
for high levels of noise, tumor-stromal interactions in fact decreased the global
mean cluster size (Fig. 3.5C).
3.3.5 Stromalized clusters are more invasive
To understand this biphasic effect of tumor-stromal interaction on the sizes of
migrating clusters (Fig. 3.5C), we then sorted the cell clusters into those in-
cluded at least one stromal cell (‘stromalized’ clusters) and those that were not
(‘unstromalized’ clusters) (Fig. 3.6A). We estimated the distance migrated by a
cluster of interacting cells by calculating the mean displacement of all cells in
the cluster at end of simulation. We then examined the relationship between
the stromalized cluster, the distance it migrated by a cluster, its stromalization
status, and its size. In the low-noise (η ≤ 0.5) regime, both the stromalized and
unstromalized clusters were smaller and displayed a smaller mean displace-
ment than clusters in the control ats = 0 simulations (Fig. 3.6B). This is caused
by the same fragmentation and consequent decrease in coherence observed in
the cyclic boundary simulations. In addition, the distribution of multiple stro-
mal cells throughout the cell population at inoculation possibly creates multiple
conflicting directional signals that propagate through many cancer cells, leading
to wandering behavior that contributes little to the mean displacement.
For larger values of η, both the size of and distance migrated by clusters de-
creases noticeably for the control simulations. The stromalized clusters separate
into a distinct coherent, far-migrating subpopulation (Fig. 3.6C). At very high
noise levels, cluster size and distance migrated are decreased for both stromal-
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Figure 3.6: A) Clusters incorporating at least one stromal cell are considered
stromalized. B) Distributions of cluster sizes and displacements for stromal-
ized and unstromalized clusters in 5 test simulations (ats = 1.0) versus control
(ats = 0) for a low-noise condition. Clusters in the control simulations varied
in size but are uniformly far-migrating. In the test simulations, stromalized
clusters tended to be larger than unstromalized clusters, though they showed
greater variance in displacement. C) Distributions of cluster sizes and displace-
ments for stromalized and unstromalized clusters in 5 test simulations (ats = 1.0)
versus control (ats = 0) for a medium-noise condition. Unstromalized clusters
in test simulations distributed similarly to clusters in control simulations both
in terms of size and displacement. Stromalized clusters in test simulations dis-
tributed distinctively from the unstromalized and control clusters, displaying
greater displacement and cluster size overall. D) Distributions of cluster sizes
and displacements for stromalized and unstromalized clusters in 5 test simula-
tions (ats = 1.0) versus control (ats = 0) for a high-noise condition. Stromalized
and unstromalized clusters from the test simulations distributed similarly with
respect to displacement, with stromalized clusters being larger overall. Cells in
the control simulations formed large, nonmotile clusters due to being unable to
significantly migrate from their points of origin. In the test simulations, tumor-
stromal interactions break the cells into small, motile clusters.
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ized and unstromalized clusters in test simulations, and for all clusters in con-
trol simulations. Regardless, stromalized clusters retain a significantly larger
mean cluster size than the unstromalized subpopulation (Fig. 3.6D). These re-
sults suggest that tumor-stromal interaction can increase both the motility of
migrating cancer cells and the number of motile cancer cells.
Notably, control simulations saw the emergence of very large clusters, on
the order of 1000 cells, with cluster displacement close to 0 (Fig. 3.6D). This is
because the cells are inoculated at high enough density to constitute a single
interacting cluster, and at high noise, most cells are unable to ‘escape the inocu-
lum cluster. Similarly to the medium-noise situation, these results suggest that
in microenvironments that present strong barriers to cancer cell migration, in-
teraction with stromal cells can aid in the escape of motile cancer cells from the
main tumor mass.
3.4 Discussion
In order to understand the effect of complex tumor-stromal and tumor-tumor
intercellular interactions on collective cancer cell migration, we have imple-
mented and analyzed the Cancer-Stromal model, a minimal computational
model for simulating the collective co-migration of two phenotypically distinct
cell types under the SPP paradigm. We have designed the model with intended
application to stromal cell-assisted cancer cell invasion, but it can theoretically
applied to any heterogeneous population where interaction between subpopu-
lations is orthogonal to interaction within subpopulations, for example a symbi-
otic or antagonistic relationship between two animal herds of different species.
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We find that, given an unbounded space in which to disperse, the addition of
tumor-stromal interaction increases the end displacement of cells within stro-
malized clusters. The presence of system-level effects in our simulations is re-
markable, considering the stromal cells constitute < 1% of all cells in the system,
and in an unbounded system only a slim minority of cancer cells will directly
interact with stromal cells in the course of a simulation.
The effect of tumor-stromal interactions on the sizes of co-migrating cell clus-
ters changes relative to the amount of noise in the system. At finite but low lev-
els of noise, positive attraction between tumor and stromal cells increases the
size of stromalized clusters over unstromalized clusters in the same system, or
clusters in systems where tumor-stromal attraction is absent. With high levels of
noise, cancer cells tend to clump in large but non-migratory clusters. Interaction
with stromal cells causes cancer cells to fragment from these static clusters into
smaller, but more invasive clusters, leading to the escape of cancer cells from
the inoculum.
Our results suggest that the presence of a small number of stromal cells ex-
pressing an attractive signal for migrating cancer cells can lead to a population-
level increase in the ability of cancer cells to migrate long distances, and
that cell clusters of significant size leaving the initial tumor site will likely
be aided in their migration by stromal cells. In realistic settings, increasing
the coherence of migrating cancer cell clusters may increase the aggressive-
ness of cancer invasion by preserving other deleterious collective phenotypes,
such as pooling of paracrine growth signals or matrix-remodeling proteases
[22, 48, 48, 70, 96, 140, 166]. Thus, the effect of tumor-stromal interaction to
increase the number of cells that are able to migrate coherently and maintain
38
cell-cell signaling may increase the fitness of the invading cancer cell popula-
tion [39, 80, 108].
It is now well established that collective migration can emerge within cancer
even without the presence of stromal cells. This phenomenon seems to be suit-
ably described by the 1-species SPP model [150, 149]. Here we add one degree
of complexity by investigating the effect of a minority of attracting cells within
on a large population. While this work is inspired by reports showing that car-
cinoma cells are attracted to EGF secreted by tumor-associated macrophages
(Wyckoff et al. 2004), it necessarily presents a simplified view. There are po-
tentially many other interaction processes existing within macrophages, tumor
cells and their complex microenvironment [39, 108, 126]. Such interactions rep-
resent further levels of complexity that are out of the scope of this study.
Nonetheless, our simple model already shows a dramatic effect on the be-
havior of the population. Specifically, the emergence of system-level increases
in migration distance in our Cancer-Stromal Model does not require a structured
environment featuring system-level signals such as chemoattractant or extracel-
lular matrix gradients [6]. We show that increased migration efficiency and es-
cape of tumor cells from a primary tumor mass can be achieved purely through
local, pairwise cell-cell interactions; no global migration trigger or directional
cue is necessary. When we investigate the spatial distribution of stromal cells
in migrating cell clusters, we find that it becomes asymmetrical and correlated
with the mean polarization of the stromal cells when tumor-stromal interac-
tion was switched on (Fig. 3.7B). This effect decreased with increasing noise
(Fig. 3.7), suggesting that tumor-stromal interaction causes the stromal cells to
emerge as leaders on the leading edge of their moving clusters. Still, on a the-
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Figure 3.7: A) We defined a leadership metric as leadership ≡ v1 · v2, where v1 is
defined as a unit vector pointing from the center of mass of a moving cell cluster
to the center of mass of all stromal cells in that cluster, and v2 is defined as the
mean polarization of all stromal cells in that cluster. The leadership metric thus
ranges from 1 to -1, where 1 represents the case that the stromal cells tend to be
at the leading edge of cell clusters and leading them, and -1 represents the case
that the stromal cells tend to be at the trailing edge of cell clusters and breaking
away. We found that changing ats from 0 to 1 caused the system-wide leadership
to increase, indicating the sorting of stromal cells to the front of clusters, and that
this effect decayed with increasing noise. B) Representative examples of moving
heterogeneous clusters from ats = 1 simulations.
oretical level, our model is distinct from collective migration models where the
population is divided into ‘leaders that are sensitive to a global directional sig-
nal (e.g. a patchy nutrient environment), and ‘followers that are not [83], since
in our case the stromal cells do not follow a global directional cue. On a biolog-
ical level, the dynamic construction of leadership we use in the Cancer-Stromal
Model reflects the experimental observation that leadership in collective cancer
cell migration can be defined not by genotype but by the spatial structure of the
cell population itself and differential access to microenvironmental factors [65].
It is also worth noting that our cancer-stromal model makes the assumption
that long-range signaling between tumor cells and stromal cells has a digital
response, vanishing at distances greater than the range of tumor-stromal inter-
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action rts. To determine whether our results are an artifact of this model as-
sumption, we performed additional simulations using a function in which the
strength of the tumor-stromal interactions decayed continuously away from the
stromal cell as
ri j
rts
with a maximum value of ats. We found that at η = 1, ats = 1,
cancer cells moved toward the center of mass of the stromal cells, which, given
the uniform distribution of cells at inoculation, was calculated to be the cen-
ter of the simulation space. This effect is a modeling artifact due to bound-
ary conditions used in simulations and has no relevance to biological reality.
When we started decreasing ats → 0.01 the artifact vanished and the simulation
yielded similar results to those using Equation 3.1. Given that the two methods
yielded similar results, and that the continuous interaction function increased
both the degrees of freedom in the model and the computation time required,
we concluded that Equation 3.1 was preferable for modeling tumor-stromal in-
teractions. In addition, within the dense and heterogeneous tissue of real solid
tumors, continuous decay over long distances may not accurately describe the
distribution of diffusible molecular signals.
Recent studies on interactions between the tumor and its stromal microen-
vironment have generated interest in targeting the microenvironment for treat-
ment, i.e. ‘ecological therapy [79]. Our results suggest that cell-cell communi-
cation among the migrating cancer cell population may serve to amplify and
increase the robustness of pro-invasive tumor-stromal interactions, propagat-
ing signals beyond the leading edge of cancer cells in direct contact with stro-
mal cells. It may thus be necessary to consider the reinforcement of pro-tumor
tumor-stromal interactions by signaling within the tumor cell population when
designing and testing potential ecological therapies. A hybrid therapy targeting
tumor-stromal and tumor-tumor intercellular signaling simultaneously may be
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required for effectiveness.
It is worth noting that the metrics we used to quantify the performance of
collective migration may be applicable to both simulated and experimental cell
systems such as in vitro cell tracking assays [150]. By collecting phenomeno-
logical data with sufficient resolution to track the positions and velocities of
individual cells and quantifying collective migration experimentally for a spe-
cific biological system (here meaning a stromal cell type and a cancer cell type),
one may parameterize or ‘tune a phenomenological model to reproduce the
collective-level behavior of an experimental system. Such hybrid experimen-
tal/computational studies have been performed in animal [107] and cellular
[150] systems. The tuned computational model may then be modified and
interrogated to make testable hypotheses for the specified system; for exam-
ple, to predict the co-migration patterns of cancer cells and tumor-associated
macrophages in a highly structured in vivo environment using data collected in
an unstructured in vitro co-culture assay, such as a chemotaxis chamber or colla-
gen gel. We hope that our expanded SPP model will help bridge the knowledge
gap between the tractability of low-perturbation in vitro experiments and the
complexity of stromal-assisted cancer cell invasion in vivo.
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CHAPTER 4
WITHDRAWAL OF THE PRO-TUMORAL PHENOTYPE IN
TUMOR-ASSOCIATED MACROPHAGES IS SUFFICIENT FOR
EFFECTIVE TREATMENT OF PLATELET-DERIVED GROWTH
FACTOR-DRIVEN GLIOBLASTOMA IN MICE
This chapter has been submitted as [30] and was in review at the time of writing.
4.1 Abstract
Understanding how to disrupt protumoral interactions between tumor cells and
their stromal microenvironment is crucial for the effective treatment of cancer.
Because of the often complex and reciprocal nature of signaling between tu-
mor cells and non-cancerous stromal cells, molecular therapies targeting stro-
mal cells may result in unexpected outcomes. We dissect the dynamics of tumor
growth and response to therapy by developing a mathematical model of tumor-
stromal interaction dynamics. Using our model, we reveal that the outcome of
treatment targeted at reeducating stromal cells away from a protumoral pheno-
type is dependent on the composition and size of the tumor at treatment initia-
tion, as well as the rate of reeducating protumoral stromal cells, and the antitu-
moral capacity of the resultant reeducated cells. We apply our model to existing
data from in vivo treatment of PDGF-driven glioma in a mouse model with the
small molecule BLZ945 targeting colony-stimulating factor 1 (CSF-1) signaling
in tumor-associated macrophages (TAMs). We conclude that the observed effi-
cacy of treatment is largely dependent on the reeducation of protumoral TAMs
and the depletion of circulating macrophage progenitors. Importantly, the an-
titumoral activity of TAMs reeducated by BLZ945 is only significant when it is
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stronger the protumoral effect of the untreated TAMs residing in the same tu-
mor. Our model provides a general description model of tumor growth and
treatment dynamics under complex interaction with the stroma and can be ex-
tended to predict long-term efficacy and outcomes of combinatorial treatments.
4.2 Introduction
Recent research has contributed to the appreciation of cancer as a disease not
only of tumor cells, but of the ecological system comprised of interactions be-
tween different tumor cell species, and between tumor cells and their microen-
vironment [101]. The understanding of tumors as ecosystems has generated
the concept of ecological therapy: targeted treatments intended not to directly
destroy malignant cancer cells, an approach which selects for drug resistance
[112], but to disrupt intercellular or cell-microenvironment interactions that en-
able invasive growth of tumor cells or the evolutionary selection for increasingly
aggressive tumor cell clones. The aim of such treatments can be to create con-
ditions that discourage the malignant expansion of the tumor cell populations
[101], reduce the selective advantage of aggressively-proliferating cells [112], or
to restore homeostasis in the diseased tissues [14].
Stromal cells such as macrophages and fibroblasts are crucial components of
the tumor microenvironment. Mutualistic relationships between cancer cells
and stromal cells play important roles in cancer progression. For example,
cancer-associated fibroblasts enable invasion [70] and angiogenesis [124], and
certain tumor-associated immune cells participate in protumoral inflammation,
driving growth [135], while endothelial cells and pericytes are necessary par-
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ticipants in angiogenesis [20]. Significantly, amongst the myriad cells of the
cancer stroma, it has been shown that tumor-associated macrophages (TAMs)
are important in promoting the growth and malignancy of many solid can-
cers, including breast [37] and glioma [100, 133]. Alternatively activated TAMs,
called M2 macrophages, are commonly considered to be anti-inflammatory and
protumoral, and have been linked to the functions of macrophages in wound
healing and regeneration, including matrix remodeling, growth factor secretion,
immunosuppression, and angiogenesis [100]. Conversely, classically activated
(M1) macrophages are considered to be anti-tumoral and pro-inflammatory
[109, 120, 134]. Due to their important role in cancer proliferation, the TAM
population presents an attractive target for therapy [24].
Tumor-derived CSF-1, as well as lactate [25, 35], and factors such as IL-4,
IL-10, and TGF-β [100] play important roles in regulating the activation state
of TAMs. In addition, in breast cancer, tumor cell-derived CSF-1 and TAM-
derived EGF form a signaling feedback loop that may be important for the main-
tenance of TAMs in the alternatively activated state [37]. Therapeutic inhibition
of the CSF-1 receptor (CSF-1R) with the small molecule PLX3397 in conjunction
with chemotherapy was shown to lead to effective reduction of breast tumors
in mouse models [50]. In certain contexts, CSF-1R inhibition as a monother-
apy has also shown efficacy. Recently, administration of a small molecule in-
hibitor of CSF-1R, BLZ945, alone led to regression of PDGF-B-driven gliomas
in mice [133], with the efficacy being more pronounced for tumors that were
larger at the time of treatment initiation (Fig. 4.1A-D). Macrophages are de-
pleted by dosing with BLZ945 in vitro; however, in in vivo murine PDGF-B-
driven gliomas (PDG), factors secreted by tumor cells including GM-CSF and
IFN-γ rescue macrophages from cell death, and treatment efficacy is associated
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Figure 4.1: The CSF-1 receptor (CSF-1R) inhibitor BLZ945 targets the tumor mi-
croenvironment and reduces PDGF-B-driven gliomas in a mouse model. (A)
Representative MRI of tumor volume decrease in a BLZ945-treated mouse. (B)
TAM-targeted CSF-1R inhibition treatment of glioblastoma using BLZ945 re-
duces tumor volume over one week. (C) Large tumors exhibit greater reduction
in size under BLZ945 treatment. (D) Diagram of cell-cell interactions in tumor
population dynamics. Data presented in A-C reproduced with permission from
[133]
and repolarization of TAMs away from a protumoral phenotype correlated with
increased phagocytic capacity, termed TAM reeducation [133].
Despite this efficacy, it is currently unknown which factors contribute to
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BLZ945 dependent tumor regression in murine PDGs. In addition to inhibiting
macrophage dependent tumor cell proliferation in vitro, CSF-1R inhibition leads
to decreased vascular density in vivo [133]. Thus, it is possible that withdrawal
of educated TAMs and their support of a protumoral microenvironment, in par-
ticular the tumor vasculature, suffices to explain the effectiveness of CSF-1R
inhibitor treatment. While BLZ945-treated TAMs also display increased phago-
cytosis of dead and dying tumor cells [133], it is unknown whether phagocyto-
sis by treated TAMs drives the striking depletion of tumor cells in the glioma
model. In addition, it is unclear if BLZ945 efficacy depends upon cytotoxic ac-
tivity of TAMs, either through direct tumor cell killing by TAMs themselves or
by engaging the adaptive immune system.
Here we investigate the mechanism of action of BLZ495 treatment by devel-
oping and analyzing a general mathematical model of the dynamics of tumor
development and the action of tumor stroma-targeting drugs. Our model de-
scribes the dynamics of and interactions between cell subpopulations in a solid
tumor in which protumoral stromal cells play a supportive role, and the alter-
ations of these interactions under targeted therapy. We find that predicting the
outcomes of ecological therapy is nontrivial, and that the efficacy of BLZ945 in
PDG tumors is likely due to a combination of loss of the educated TAM pheno-
type and antitumoral cytotoxicity of reeducated TAMs, though the former alone
may suffice for effective treatment.
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4.3 Mathematical model and assumptions
We construct a mathematical population dynamics model using ordinary differ-
ential equations to describe the progression and treatment of TAM-dependent
tumors using macrophage-targeted therapy. The model has four state variables,
each representing a cell population: Tumor cells (T ), nave macrophages (N),
educated macrophages (E) and reeducated macrophages (R) (Fig. 4.1D). The
model is built on four assumptions:
Assumption 1
Tumor is initiated with 1 tumor cell and no other cellular species (T = 1,N = E =
R = 0), and tumor growth is self-limiting without stromal cells. We assume that
tumor cells (T ) initially proliferate independent of macrophages with coefficient
µ. Proliferation is inhibited and glioma cells are driven to quiescence or death
through competition for limited microenvironmental resources as they increase
in density with coefficient c, resulting in self-limiting logistic growth [19]. The
coefficients µ and c define the basal carrying capacity κ =
µ
c
, the maximum size
to which a tumor can grow through cell-autonomous processes.
Assumption 2
The presence of tumor cells triggers recruitment of nave macrophages or mi-
croglia (N) from either the peripheral brain, in the case of glioma, and/or the
systemic circulation [133, 10, 7]. We model the rate of recruitment as a function
of the tumor cell population size using a Hill function. Use of the Hill func-
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tion allows us to define a critical tumor cell population size Tcrit. In a tumor
much smaller than this critical size, the rate of macrophage recruitment will be
negligible, and in a much larger tumor, recruitment will be saturated; i.e. the
rate of macrophage recruitment will be invariant with change in tumor size and
equal to the maximum rate of recruitment, rmax. The steepness of this transition
is determined by the Hill parameter h.
Assumption 3
Recruited macrophages are educated by interaction with tumor cells into a
protumoral TAM phenotype, whose presence relaxes microenvironmental con-
straints on tumor cell growth. Upon infiltration of the tumor microenvironment,
nave macrophages are educated through paracrine interaction with tumor cells
into a protumoral TAM phenotype (E) [162]. These educated macrophages pro-
mote the growth of tumor cells, for example, through microenvironmental re-
modeling, immunosuppression, and promotion of angiogenesis [162, 76, 105].
Thus, the presence of educated TAMs in the tumor microenvironment effec-
tively raises the carrying capacity of tumor cells above the basal carrying capac-
ity κ = µc . In effect, this renders our model a relative of established dynamic
carrying capacity models for cancer growth [19, 136], but with the dynamics of
the carrying capacity increase being modulated by the cell population dynamics
instead of explicitly described.
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Assumption 4
TAM-targeted treatment changes the rate parameters governing interactions be-
tween cell populations. We assume that TAM-targeted drugs have an on-or-
off effect, and do not introduce new processes to the network of intercellu-
lar signals, but modify the rates of existing interactions and of switching be-
tween TAM phenotypes. To this end, we introduce five parameters of varying
value that determine the effect of treatment on interactions between cellular
subpopulations. Reeducated neutral or anti-tumoral TAMs (R) induce cytotox-
icity against tumor cells determined by the parameter α. The drug inhibits the
protumoral signaling of educated TAMs by a fraction β; for example, this could
represent the effect of inhibitors that negate angiogenic signals produced by
educated TAMs. The rate of nave macrophage education is modulated by the
coefficient γ. The rate of reeducation of educated TAMs is modulated by the
coefficient δ. Finally, the rate of recruitment of macrophages and microglia is re-
duced by a fraction . The values of these parameters are only used when drug
is present in the tumor; for untreated or vehicle-treated tumors, they default to
the values of β = 0, γ = 1, δ = 1,  = 0. α retains its set value regardless of drug
presence. By including the possibility of multiple alterations to the intercellu-
lar signaling network, we account for the variation in dynamics of anti-TAM
therapy between different tumors.
Figure 4.1E shows a diagram of tumor-macrophage interactions and the pa-
rameters affected by treatment in our model. The full set of differential equa-
50
tions constituting the model is as follows:
dT
dt
= µT − cT 2 + g(1 − β)E − αRT (4.1)
dN
dt
= rmax
1
1 + (Tcrit/T )h
− γk1NT + k2E (4.2)
dE
dt
= γk1NT − k2E − δk3E + k4R (4.3)
dR
dt
= δk3E − k4R (4.4)
Table 4.1 lists the model parameters and their definitions. Calculations for esti-
mating fixed-value parameters are described in the Methods section.
We performed numerical simulations of the model and analyzed the equa-
tions to predict the long-term tumor size, composition, and growth rate. We
make further simplifying assumptions about the model dynamics to obtain the
latter analytical solutions.
4.4 Rationale of parameter values
4.4.1 Estimation of tumor cell population size from MRI data
Vehicle-treated tumors have typical volumes of 10 − 100mm3, as measured by
MRI. Approximating cells as cubes ≈ 10µm on a side (BNID 108941, [114]), a
typical eukaryotic cell has a volume of 10−6mm3. Hence, we estimate a tumor of
volume order 10mm3 to contain on the order of 107 cells, and a tumor of volume
order 100mm3 to contain 108 cells.
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Parameter Definition Dimensions
(ND = non-
dimensional)
Values used Rationale
µ tumor cell growth rate
constant
Tumor
cell/time
0.7 cells/day See 4.4.2
c tumor cell competition
rate constant
1/(tumor cell *
time)
7 × 10−8 day See 4.4.3
g coefficient of promotion
by educated TAMs
1/(stromal cell
* time)
6.3 × 10−7
/(stromal cell *
day)
See 4.4.4
rmax max rate of recruitment of
stromal cells
Stromal
cell/time
106 stromal
cells/day
See 4.4.5
Tcrit critical tumor cell popu-
lation size for recruitment
of stromal cells
Tumor cell 107 cells See 4.4.6
h Hill constant of recruit-
ment rate function
ND 2 See 4.4.6
k1 rate constant of education
of naı¨ve stromal cells to a
pro-tumoral phenotype
1/time 1000 See 4.4.6
k2 rate constant of reversion
of educated stromal cells
to the naı¨ve phenotype
1/time 0 See 4.4.6
k3 rate constant of reeduca-
tion of educated stromal
cells to a neutral or anti-
tumoral phenotype
1/time 0.001 See 4.4.6
k4 rate constant of rever-
sion of reeducated stro-
mal cells to the educated
phenotype
1/time 1 See 4.4.6
α cytotoxicity induced by
reeducated stromal cells
1/(stromal cell
* time)
[10−9, 10−3]
/(stromal cell *
time)
See 4.4.6
β fractional inhibition of
pro-tumoral signaling
from educated stromal
cells by treatment
ND [0, 1] See 4.4.6
γ modulation of educated
rate by treatment
ND [0.001, 1] See 4.4.6
δ modulation of reeduca-
tion rate by treatment
ND [1, 104] See 4.4.6
 fractional inhibition of
stromal cell recruitment
by treatment
ND [0, 1] See 4.4.6
Table 4.1: Parameters used in the tumor-macrophage population dynamics
model
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4.4.2 Estimation of tumor cell growth constant
Assuming a population of T cells undergoing exponential growth, the effective
growth coefficient µ can be calculated from the population doubling time τ:
T (τ) = T (0)eµτ (4.5)
T (τ)
T (0)
= 2 = eµτ (4.6)
µ =
ln 2
e
(4.7)
4.4.3 Estimation of tumor cell competition constant
Linear regression of tumor reduction as a function of initial tumor size predicts
tumors of size approximately 20mm3 will not be reduced by BLZ945 treatment.
Assuming that the majority of cells in the tumor are tumor cells, and that this
volume is equal to the basal (logistic) carrying capacity of the tumor cells, which
is a function of the tumor cell growth and competition constants κ = 20mm3 ≈
107cells =
µ
c
, therefore
c = 7 × 10−8(cells × day)−1 (4.8)
4.4.4 Estimation of educated TAM promotion constant
Experiments show TAMs to constitute roughly 10% of all cells in vehicle-treated
gliomas. Assuming this composition is steady-state,
53
f ∗mac =
c
c + g
= 0.1 (4.9)
Therefore,
g = 6.3 × 10−7(TAMs × day)−1 (4.10)
4.4.5 Estimation of max macrophage/microglia recruitment rate
The long-term growth rate of vehicle-treated tumors is predicted to be
(
dT
dt
)∗
=
grmax fE
c
(4.11)
Estimating from MRI measurements, the growth rate of vehicle-treated
tumors during the final week of experiment is constant and approximately(
dT
dt
)∗
= 107 cells/day. Assuming all TAMs in untreated tumors are educated
( fE ≈ 1), we estimate
rmax = 106 macrophages/day (4.12)
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4.4.6 Other parameters
Tcrit
Simulations with various values of Tcrit as a function of κ =
µ
c
were performed
(see 4.6.1). Though variations in
Tcrit
κ
produced noticeable variations in the
early growth stage of simulated untreated tumors, the long-term dynamics were
identical. From the data in [133], the value of
Tcrit
κ
cannot be determined. We
thus used Tcrit = κ for simplicity in subsequent simulations.
h
We used a Hill function with exponent 2 to model a nonlinear transition in the
dynamics of monocyte recruitment from negligible at low glioma cell count to
saturated at high glioma cell counts. An upper limit for monocyte influx is rea-
sonable, given that the circulating/peripheral monocyte population and tumor
blood vessel density are finite. Saturation dynamics in the form of Michaelis-
Menten functions have conventionally been used to model the dynamics of im-
mune cell recruitment [47], identical to a Hill function with exponent 1. Using
an exponent of 2 additionally models weak recruitment of monocytes at low
glioma cell count. This can be interpreted as tumor inflammation, which corre-
lates with immune cell infiltration and malignancy, being triggered only when
the glioma cell population size and cellular stress become significant [108].
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ki
Without time-resolved imaging of expression of polarization marker genes in
macrophages, it is difficult to set biologically accurate values for the rate con-
stants of macrophage phenotypic transitions. Values were chosen such that al-
most all TAMs in untreated tumors would be educated (i.e.
E
N + E + R
≈ 1).
The actual relative abundance of educated TAMs in vivo may differ. Results
from [133] suggest several differentially-regulated genes associated with the
M2 polarization of macrophages that could be useful as an in vivo marker for
macrophages expressing the educated phenotype, including Arg1 and Mrc1.
However, though increased expression of these genes on the population level
correlates with increased tumor growth, macrophage polarization occurs along
a spectrum, and it is possible not all macrophages expressing these genes have
a protumoral educated phenotype. More rigorous methods of categorizing
macrophage phenotypes with respect to their phenomenological impact on the
growth of glioma cells is required to accurately determine these parameters.
Setting ki  µ, c, g could possibly lead to macrophage polarization dynamics
lagging the bulk tumor cell and macrophage population dynamics, and conse-
quently generate oscillatory behavior. However, this would require the time
scale of macrophage intracellular regulatory signaling be far longer than the
time scale of cellular apoptosis and macrophage infiltration. Without further
knowledge of the dynamics of regulatory networks governing macrophage po-
larization, this possibility seems unlikely to be realistic.
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α, β, γ, δ, 
The five parameters governing the dynamics of TAM reeducation treatment rep-
resent phenomenological values of putative alterations to cell-cell interactions.
We performed a thorough parameter scan of each parameter (between 0 and 1
for parameters representing relative inhibitions in rate, where 0 is full inhibition
and 1 is no inhibition; across orders of magnitude for parameter representing
absolute values). Parameter values were further fixed for the specific case of
BLZ945 treatment of glioma (see 4.6.3).
4.5 Methods
A system of ordinary differential equations (eqs. 4.1-4.4) was implemented in
the Matlab programming language. The equations were solved numerically
using the integration routine ode15s.
4.6 Results and discussion
4.6.1 Simulations of untreated tumors
Analysis of the model reveals that in tumors that depend on educated TAMs
for progression, tumor growth occurs in compositionally distinct stages. Ini-
tially, when the tumor size is small, macrophage recruitment is negligible and
growth is limited by the intrinsic growth rate of cancer cells. At T ≈ Tcrit,
macrophage recruitment accelerates until the rate of recruitment stabilizes to
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rmax. As a result, the macrophage content of the tumor increases rapidly. The re-
cruited macrophages are educated by interactions with tumor cells and display
the protumoral TAM phenotype, increasing the rate of glioma cell proliferation
and rescuing tumor growth from self-limitation due to previous microenviron-
mental scarcity.
As a result, tumor growth occurs in three compositionally distinct phases:
an initial phase of macrophage-poor, glioma cell-autonomous growth, followed
by a transient phase of accelerating TAM enrichment and growth, and finally a
linear growth phase in which glioma cells and macrophages rapidly increase
in number while remaining in constant proportion (Fig 4.2). Assuming all
macrophages in the tumor are reeducated TAMs, the steady-state fraction of
TAMs in untreated gliomas
(
f ∗mac
)
can be predicted as a function of the glioma
cell competition coefficient c and the educated TAM promotion coefficient g:
f ∗mac =
( T
T + M
)
=
c
c + g
(4.13)
Given the above solution for the projected TAM content of a tumor, and assum-
ing the equilibrium between naı¨ve and educated TAMs is rapidly reached, the
rate of malignant glioma growth in the long-term
(
dT
dt
)∗
is a function of the pro-
motion coefficient, the maximum rate of macrophage recruitment rmax, and the
competition coefficient: (
dT
dt
)∗
=
grmax fE
c
(4.14)
Notably, the final linear phase of tumor growth is faster than early, macrophage-
free growth. This corroborates experimental observations that macrophage in-
filtration precedes the onset of angiogenesis and malignancy in vivo [25].
The specific dynamics of the transition from initial low-macrophage growth
to malignant macrophage-dependent growth depends on whether the basal car-
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Figure 4.2: Effects of varying Tcrit
κ
on tumor growth dynamics. Left axes, top row:
tumor cell count as a function of time. Left axes, bottom row: tumor cell growth
rate as a function of time. Right axes: relative macrophage abundance as a func-
tion of time. (A) Tcrit
κ
< 1 generates an initial slow phase of TAM-independent
growth of constant rate, followed by a fast phase of concurrent TAM-dependent
and TAM-independent growth, and finally a slower phase of TAM-dependent
growth only of constant rate. (B) Tcrit
κ
= 1 generates an initial slow phase of
TAM-independent growth of constant rate followed by a smooth acceleration
to TAM-dependent only growth of constant rate, with no overlap between the
two phases. (C) Tcrit
κ
> 1 generates an initial slow phase of TAM-independent
growth of constant rate, followed by an exponential TAM-independent growth
and quiescence, followed by TAM-dependent growth of saturating rate.
rying capacity of the glioma cells is reached before the transition from slow
to rapid macrophage recruitment, that is the ratio of parameters
Tcrit
κ
. When
Tcrit
κ
≤ 1, rapid macrophage recruitment begins before the basal carrying capac-
ity is reached: this leads to a transient phase when TAM-independent growth
and TAM-dependent growth proceed simultaneously, resulting in very fast
growth until the basal carrying capacity is reached, after which the tumor size
increases more slowly and only through TAM-dependent growth (Fig. 4.2A).
When
Tcrit
κ
= 1, the tumor progresses via TAM-independent growth until reach-
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ing the basal carrying capacity, followed immediately by a transition to TAM-
dependent growth (Fig. 4.2B). When
Tcrit
κ
≥ 1, the tumor progresses via TAM-
independent growth until reaching the basal carrying capacity, followed by a
period of apparent tumor dormancy. However, during this quiescent phase, the
tumor continues to recruit and educate macrophages, thus enabling growth at
a lower rate. Once the glioma cell population size reaches Tcrit, macrophage re-
cruitment accelerates, and the tumor enters the final phase of fast, malignant
growth (Fig. 4.2C). Our model thus reveals multistage compositional dynamics
in early glioma growth that may be difficult to detect in vivo.
Interestingly, in the case of
Tcrit
κ
= 1, the dynamics generated by our model
resemble those of the established exponential-linear model featuring two dis-
tinct growth phases separated by a threshold tumor mass, which has been
shown to describe accurately the growth of ovarian and colorectal [145] and
breast [19] xenograft tumors in mouse models. Our model thus reveals a pos-
sible cancer ecological explanation for previously observed bulk tumor growth
dynamics that may apply to solid tumors in different tissues.
4.6.2 Simulations of treated tumors
We first developed a generalized model of tumor treatment based on targeting
the macrophage compartment of stromal cells. Although this model was moti-
vated by the success of BLZ945 glioma treatment in glioma models, the model
presented here also allows investigation of other treatments that target TAMs.
We assume that the properties of any TAM-targeted therapy fall within a five-
dimensional parameter space (α, β, γ, δ, ). After performing a parameter scan of
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this space (Table 1), we find that qualitative treatment outcomes fall into one of
four categories:
1. reduced and suppressed (regression)
2. reduced, but not suppressed (tumor rebounds after reaching a minimum
size: relapse)
3. not reduced, but suppressed (stasis)
4. not reduced, and not suppressed, with tumor progression continuing at a
slowed rate (progressive disease) (Fig. 4.3).
The model also predicts that the tumor cell population under continuous
treatment will achieve a minimum size before becoming suppressed or before
rebound occurs. For purposes of analysis, we assume that TAM reeducation is
effectively instantaneous, all macrophages in the tumor adopt either the edu-
cated TAM or the reeducated TAM phenotype, and that tumor reduction under
treatment occurs before any recruitment of nave macrophages into the tumor.
Under these assumptions, the reduction in tumor size achieved before relapse
or suppression is a function of the relative abundances of educated and reedu-
cated TAMs, the basal carrying capacity of tumor cells, as well as the tumor cell
population size at the time of treatment initiation.
∆T = T (td)
[
1 −
(
(1 − β) f ∗E −
α
g
f ∗R
)]
− κ (4.15)
Where T(td) is the number of tumor cells at the time of treatment initiation, and
f ∗E , f
∗
R are the post-treatment steady-state solutions for the relative abundances
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Figure 4.3: Qualitative categories of TAM-targeted treatment outcomes. Tran-
sient tumor reduction efficacy does not guarantee effective long-term suppres-
sion of tumor progression, as illustrated by the panel “relapse”.
of educated TAMs and reeducated TAMs. These relative abundances are deter-
mined from the treatment parameter δ and the equilibrium ratio of reeducated
to educated TAMs Kr, which can be calculated from the rate constants of TAM
62
reeducation and reversion to the educated phenotype:
Kr =
k3
k4
(4.16)
f ∗E =
1
1 + δKr
(4.17)
f ∗R =
δKr
1 + δKr
(4.18)
Assuming the parameters governing intercellular interactions are consistent
between pre-treatment tumors, this translates into a positive linear relationship
between the total number of cells in the tumor at time of treatment initiation
and residual tumor size after treatment. This replicates the linear correlation
between pre- and post-treatment tumor size seen in in vivo experiments with
the PDG model (Fig. 4.1C). It is also evident that any reduction of the tumor
beneath the basal carrying capacity (Tmin < κ) requires the reeducated TAMs
to possess antitumoral cytotoxicity greater than the ratio of the post-treatment
promotional coefficient g(1 − β) to the post-treatment reeducated to educated
TAM ratio δKr:
α >
g(1 − β)
δKr
(4.19)
Similarly to the pre-treatment case, we can solve the equations to obtain the
long-term change in tumor cell carrying capacity under continuous treatment,
which will determine whether tumor rebound occurs. The rate of change in
tumor cell carrying capacity is equal to the rate of change of the steady-state
solution for the tumor cell population size:
dT
dt
∗
=
dM
dt
1
c
(g(1 − β) f ∗E − α f ∗R) (4.20)
Assuming macrophage recruitment is the only source of fluctuations in the to-
tal number of macrophages in the tumor, that is, all other processes such as
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macrophage cell death and in situ proliferation sum to zero:
dM
dt
= (1 − )rmax 11 + (Tcrit/T )h (4.21)
From this solution it is evident that tumor growth will be successfully sup-
pressed by continuous treatment if at least one of the following conditions is
met:
1. The tumor cell population is reduced to a small enough size, such that
1
1 + (Tcrit/T )h
≈ 0;
2. Recruitment of nave macrophages is effectively blocked, i.e.  = 1;
3. The cytotoxic effect of reeducated macrophages is high enough such that
α >
g(1 − β)
δKr
.
Either of the first two conditions ensures further macrophage recruitment will
be inhibited, preventing TAM-dependent tumor relapse, while the third con-
dition means any continued macrophage recruitment will have an overall an-
titumoral effect due to treatment-induced macrophage reeducation. On the
contrary, if none of these conditions are met, the tumor may rebound under
continuous treatment, despite initially effective tumor reduction. Our model
thus reveals a mechanism for the non-evolutionary emergence of resistance to
anti-TAM therapy under continuous treatment, enabled purely by population
dynamics.
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4.6.3 Applying the model to explain BLZ945 mechanism of ac-
tion in glioma mouse models
We then apply our generalized mathematical model to the specific case of
BLZ945 treatment of PDGF-driven glioblastoma in mice. The following exper-
imental observations [133] allow us to constrain the model of untreated tumor
growth:
• Magnetic resonance imaging (MRI) of vehicle-treated mice shows linear
expansion of tumor volume within a seven-day observation period post-
treatment initiation (Fig. 4.1A)
• linear regression of fractional tumor reduction as a function of tumor size
at time of treatment, as measured by MRI, predicts that tumors smaller
than ≈ 20mm3 will initially continue to grow during BLZ945 treatment,
slowing and eventually arresting as T approaches κ (Fig. 4.1C).
• immunostaining and flow cytometry of vehicle-treated tumors show rela-
tive TAM abundance of 10-20% [133].
The precise dynamics of early tumor growth in PDGF-driven glioma are un-
known and may differ from other TAM-rich solid tumors. Our model predicts
that the value of Tcrit has no impact on the long-term tumor growth rate, which
makes it is difficult to estimate the value from in vivo MRI measurements. These
data represent later TAM-rich stages of glioma growth.
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In addition to this, empirical values for Tcrit and κ may represent glioma cell
counts smaller than the MRI detection threshold and thus are below the detec-
tion limit. Research has shown that myeloid infiltration into murine gliomas
is largely dependent upon HIF-1α signaling and subsequent CXCL12 mediated
recruitment [55]. Further studies have shown a similar mechanism at play in
response to irradiation therapy [99]. We infer from these studies that cellu-
lar stresses experienced during early gliomagenesis and conventional therapy
are indicative of the stresses that a tumor experiences as it reaches its basal
carrying capacity, interpretable as the maximum allowable tumor size with-
out macrophages. Thus, we assume that the rate of macrophage recruitment
increases dramatically as T → κ. In other words, we assume that the critical
tumor size equals the tumor intrinsic carrying capacity: Tcrit = κ.
In preclinical experiments, BLZ945 treatment is initiated when a tumor of de-
tectable size is observed via MRI, usually around week 5 post-tumor initiation;
mice are thereafter dosed daily with drug [133]. We thus assume that BLZ945
enters and remains in the system at a constant level after treatment initiation.
When BLZ945 is present, educated TAMs are converted to the reeducated phe-
notype. We simulate tumor growth by initializing simulations (day 0) with 1
glioma cell and no other cellular species present. As in the experiments, we fix
the time of treatment initiation at tdrug = 35 days. Simulations were run for 42
days.
Fromin vivo experiments, it is known that circulating monocytes and brain-
resident microglia, the presumed precursors of TAMs, are depleted by BLZ945,
eliminating the reservoir of macrophages that may be recruited to the tumor to
expand the carrying capacity [133]. We thus assume that macrophage recruit-
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ment post-BLZ945 treatment is completely inhibited, or  = 1. From our solu-
tion to the generic model above, this is sufficient to explain the lack of tumor
rebound observed in the experimental system (Fig. 4.3).
The initial education of naı¨ve macrophages into a protumoral phenotype
and inhibition of the antitumoral phenotype is likely to be driven by a complex
set of signals not limited to CSF-1, including CCL2 [169], GM-CSF [144], IL-4, IL-
10, and IL-13 [76, 110]. We thus assume that the education of naı¨ve macrophages
is not inhibited by BLZ945, and therefore γ = 1.
Finally, if any TAMs remain in the educated compartment, it can be assumed
that the ability of glioma cells to benefit from their presence is not altered by
BLZ945, thus we set β = 0 [133].
Therefore, after considering the constraints imposed by experimental obser-
vations, the five-dimensional parameter space of the generic treatment model is
reduced to a two-dimensional subspace (α, δ), for the specific case of BLZ945
treatment of PDGF-driven glioblastoma. In other words, the efficacy of the
treatment is dependent only upon the anti-glioma cell cytotoxicity induced by
the reeducated TAMs (α) and the rate of TAM reeducation (δ). We performed
a parameter scan of the two-dimensional phase space across seven orders of
magnitude of α and five orders of magnitude of δ and found two distinct re-
gions of behavior separated by the line α =
g
δKr
(Fig. 4.4). In the lower region,
the tumor is not completely eliminated, even though further progression is sup-
pressed. The efficiency of the regression is mainly a function of the reeducation
(parameter δ). In the upper region, the tumor cell population is completely
eliminated by BLZ945 treatment. The influence of α on the outcome of treat-
ment largely disappears with values < 10−7, meaning the cytotoxicity induced
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Figure 4.4: Minimum residual tumor size relative to the tumor size at time of
treatment initiation in the phase space of (δ, α). White dotted line indicates
the separation between the upper-right domain where the tumor cells are com-
pletely depleted, and the lower-left domain where they are not, and represents
the critical reeducated TAM cytotoxicity relative to rate of reeducation α = g
δKr
.
When α < 10−7 = g reeducated TAM cytotoxicity has a negligible effect on treat-
ment outcome, and efficacy is determined solely by the rate of reeducation. In-
sets: representative time courses.
by reeducated TAMs is weaker than the protumoral effect of educated TAMs,
and the loss of educated TAMs and the consequent withdrawal of a protumoral
stromal microenvironment are responsible for generating the bulk of treatment
efficacy. With α > 10−7), meaning the cytotoxicity induced by reeducated TAMs
is stronger than the protumoral effect of educated TAMs, antitumoral cytotoxi-
city in reeducated TAMs becomes a significant factor in treatment outcome.
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4.7 Discussion
Ecological interactions amongst cancer cells and between cancer cells and the
stroma drive the population responses of tumors to physiological challenges
during progression and treatment, leading to malignancy and drug resistance
[123]. Quantitative understanding of cancer ecology will be crucial to the de-
velopment of successful therapeutic strategies, and effective categorization of
disease based on recognition of population-level ecological ‘biomarkers such
as tumor composition and intratumoral heterogeneity. Mathematical modeling
can be a powerful tool to describe and predict the dynamics of disease progres-
sion and treatment.
Pro-tumoral signaling from stromal cells such as TAMs (but also including,
for example, cancer-associated fibroblasts [142]) perform essential functions in
tumor progression. Our model shows the growth of such a tumor, composed of
a heterogenous and mutualistically-interacting population of tumor and stro-
mal cells, and exhibits complex population dynamics and fluctuations of popu-
lation composition. Similarly, the post-treatment dynamics of the cellular popu-
lations show that outcomes can be nonlinear and vary over time, as well as de-
pend on the state of the tumor at time of treatment initiation. Our results raise
the possibility that the assessment of treatment efficacy for general stromal-
targeted therapies is thus complicated even without considering the emergence
of resistance through evolutionary mechanisms, and may require differentiating
between short-term tumor regression and long-term tumor suppression.
Owing to factors such as tumor-associated inflammation [57] and the
fragility of tumor vasculature [46, 115], the tumor microenvironment is highly
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heterogeneous and unstable [59, 69, 71, 155]. Such an unstable microenvi-
ronment may require constant remodeling to maintain its pro-tumoral prop-
erties. TAMs expressing an alternatively activated, regenerative phenotype
may play important roles in maintenance of a pro-tumoral microenvironment
[81, 134, 141]. In treating a tumor system dependent on TAMs for microenvi-
ronmental maintenance with TAM reeducation factors, it may not be necessary
to induce expression of an anti-tumoral macrophage phenotype to successfully
regress the tumor. However, anti-tumoral killing by reeducated TAMs can sup-
press tumor regrowth in cases where residual macrophage recruitment and ed-
ucated TAMs persist.
Specific to the activity of BLZ945 in the glioma model, we find induction of
anti-tumoral cytotoxicity in the re-educated TAMs not to be required for the ef-
fectiveness of treatment seen in in vivo experiments [133]. Indeed, our model
predicts that when anti-tumoral cytotoxicity mediated by re-educated TAMs is
weaker than pro-tumoral signaling in educated TAMs, this anti-tumoral activ-
ity will have negligible impact on treatment outcome (Fig. 4.4). However, this
cytotoxicity-independent efficacy is dependent on the inhibition of macrophage
recruitment, possibly due to the depletion of circulating monocytes, and alter-
native CSF-1R inhibitors or TAM-targeted agents that do not deplete circulating
monocytes or inhibit their recruitment may have different outcomes. Further-
more, variations between tumors, or between tumors of different types, mean
that some tumor cell populations may receive a greater beneficial effect from ed-
ucated TAMs, i.e. g is greater. For these tumors, we predict with our model that
reeducated TAMs must induce greater cytotoxicity for TAM-targeted ecological
therapy to be effective, assuming the efficiency of re-education is the same.
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The complexity of tumor-TAM signaling provides many possible mecha-
nisms for intervention by treatment, and our general model provides a means
to predict the therapeutic efficacy of those interventions. For example, the effect
of inhibiting signals from pro-tumoral stromal cells, such as microglia-derived
IL-6 in glioma [169], without depleting or altering the phenotypes of the stro-
mal cells, may be modeled by setting the parameter β > 0. The action of anti-
angiogenic factors such as anti-VEGF inhibitors [75] could be similarly modeled.
Interestingly, the (δ, α) phase space of BLZ945 treatment shows that the domains
of full response and no response are separated by a relatively narrow boundary,
implying that for some tumors with limited or no response, a small change in
parameters could generate a large change in response, possibly leading to full
regression of the tumor. This suggests a role for combinatorial treatments. For
example, BLZ945 combined with a hypothetical treatment increasing the anti-
tumoral immune activity associated with reeducated TAMs (α) by 10-fold could
drive a partially responsive or non-responsive tumor to full response. For this
reason, TAM reeducation could serve as a powerful complement or alternative
to treatments aimed at depleting or preventing the recruitment of macrophages
[23].
We acknowledge that our model does not capture the full complexity of
tumor-stromal ecology and perturbations to it. Current analyses do not inves-
tigate the response of tumor ecology to conventional treatments, such as ra-
diotherapy and chemotherapy, which rapidly deplete tumor cells but do not
target stromal cells. Modeling the response of the tumor-stromal system to a
sudden decrease in tumor cell count could be implemented in a future appli-
cation of our model. We also have not modeled the protective effect of tumor
cell-secreted factors on TAMs in the face of CSF-1R inhibition, which specifi-
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cally prevented TAM killing, while microglia and other normal macrophages
were depleted [133]. Conceivably, loss of tumor cells upon initial TAM reedu-
cation followed by TAM loss due to depletion of those protective tumor cells
could result in a feedback that would suffice for effective treatment. Finally,
it would be interesting to investigate the possibility of dynamic regulation of
multiple independent pro-tumoral signaling pathways within educated TAMs,
such as IGF-1 [68], as each macrophage phenotypic compartment is modeled as
internally homogeneous and invariant with time. In sum, we present a general
mathematical model to predict the outcomes of tumor growth and treatment
with respect to the complex interactions between tumor cells and associated
stromal cells, as well as alterations in their respective phenotypes after targeted
therapy. We have used our model to examine possible factors explaining the ef-
ficacy of BLZ945 treatment of PDGF-driven glioma in a mouse model [133]. The
model may be expanded to predict longer-term outcomes of continued treat-
ment, including relapse after discontinuation of treatment, or loss of treatment
effectiveness through emergence of resistance.
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CHAPTER 5
CONCLUSIONS
5.1 The importance of being collective
In light of increased capability for characterizing tumors in terms of genomic al-
teration and gene expression on a per-patient basis, there has been anticipation
that the next paradigm shift in cancer treatment will come in the form of per-
sonalized medicine [102]. Under this paradigm, the disease of each cancer patient
would be categorized into a subtype based on identification of genomic and
transcriptomic biomarkers, after which the most effective course of treatment
for that subtype would be applied.
Despite the promise of personalized treatment, inter- and intra-tumoral het-
erogeneity present several possible obstacles to its success [61]:
• The initial number of qualified recipients of personalized therapy might
be small, as driving genetic alterations are difficult to identify in many
cancers, attributable to phenotypic complexity and genomic instability of
transformed cells [56];
• while sophisticated and specific treatments may be highly effective, the
number of cases in which they are useful may be limited, as driving ge-
nomic events that recur across cancer types are rare [3];
• due to intratumoral clonal heterogeneity, targeted treatments are unlikely
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to affect all cells in the tumor, leading to high risk of relapse driven by
non-responsive clones.
In short, there is a threat that perceived tumor complexity will explosively
increase with diagnostic resolution, resulting in the disintegration of cancer into
a plethora of individual complex diseases for which costly treatments must be
designed respectively, to a point that the impact of any novel targeted treatment
on the overall long-term cancer risk of the patient population becomes negligi-
ble and not worth the investment necessary to develop it. In anticipation of this
explosion of complexity, it is now essential to understand not only how tumors
are different, but how they are the same: to focus on discovering first principles
governing the behavior of tumors as intricate multicellular systems that are gen-
eralizable across patients and cancer types despite underlying heterogeneity at
the cellular and molecular levels.
Without understanding these principles, the qualitative large-scale and long-
term outcomes of molecular events cannot be accurately predicted, and findings
cannot be transferred between mechanistically diverse systems. Because of this,
phenomenological models, such as those I have described here, inferred from
and validated against data will form a necessary complement to mechanistic
models and experiments. For while a mechanistic view of cancer may iden-
tify therapeutic targets, phenomenology describes the effects of perturbations of
mechanism on the flow of information through the system. Thus, phenomeno-
logical models can provide the means of predicting the observed evolution of a
system from its observed initial state.
Existing efforts to study complex systems such as cancer cell populations
and cellular signaling networks often take a hypothesis- and modeling-driven
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approach. Indeed, the two projects presented in this dissertation fall under this
category. Such approaches risk obscuring not only the true complexity and mag-
nitude of biological populations or signaling networks, but perhaps more im-
portantly, the characteristic ability of real biological systems to produce relevant
behaviors on multiple time- and length-scales [104]. The emerging challenge is
to learn the organizing principles of complex biological networks and popula-
tions directly from data, including large-scale genomic and transcriptomic data,
which is now becoming increasingly available [12]. In closing, I will outline
several proposals for experimentally probing the ecological and evolutionary
complexity of cancer in ways that can also yield meaningful theoretical insight.
5.2 Proposed experimental approaches to cancer ecology and
evolution
5.2.1 From ‘big data’
Intratumoral cellular heterogeneity in solid tumors on the genomic [74, 168]
and phenotypic [130] levels has been observed using sequencing techniques.
Although such datasets can reveal the cellular composition of tumors, an extra
layer of analysis is necessary to infer the population structure—that is, the topol-
ogy of interactions between cellular subpopulations that generate and sustain
the expansionary population dynamics that characterize malignancy.
One promising course of research would be to infer quantitative, phe-
nomenological models of interactions between cell subpopulations in cancers
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from sequencing data. Inspiration for this approach can be found in recent
studies of the human gut microbiome [148, 60]. In these works, time se-
ries of the abundances of bacterial species (more accurately operational taxo-
nomic units, or OTUs) in human digestive systems are obtained by sequenc-
ing microbial DNA, then quantifying the abundance of each bacterial species
through qPCR amplification of distinguishing 16S ribosomal RNA. Coefficients
for Lotka-Volterra population dynamics models are then inferred from time se-
ries species abundances using various techniques.
Within the population of transformed cells, genome sequencing will be use-
ful in reconstructing the phylogenetic tree of transformed clones [51]. The major
challenge in applying this methodology to cancer is that much of intratumoral
phenotypic heterogeneity is driven by microenvironmental regulation and the
plasticity of intracellular signaling networks. Hence, distinctive genomic varia-
tions between functional cellular subpopulations in tumors are likely to be rare.
All untransformed stromal and infiltrating immune cells, in particular, will be
genomically identical with each other and with all other untransformed cells of
the host. It thus becomes necessary to characterize cells phenotypically on the
level of gene expression, if not function.
A distribution of cells in gene expression space can be obtained through
single-cell transcriptome profiling [43], and categorized into transcriptional sub-
types using machine learning methods such as unsupervised clustering. Alter-
natively, bulk tumor transcriptome data could be decomposed along mean gene
expression patterns of different cell types to reconstruct the abundances of cel-
lular subpopulations. An example of decomposition of expression data along
expression patterns characteristic cell types exists for identifying putative can-
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cer stem cells in acute myeloid leukemia [72]. Time-resolved data of this kind
would allow the inference of a dynamical model of interactions between sub-
populations from the time correlation of their abundances.
As time series data may be difficult to obtain in a clinical environment, an
alternative approach could be to search for correlations between phenotypic
subpopulations across samples of different tumors, or samples from different
spatial locations within the same tumor. As correlation between variables in a
network does not imply a direct interaction, a stepwise regression method such
as that used in [60] could be used to weed out indirect interactions from the
putative ecological network.
A parallel path could be to discover predictive population-level disease
markers within the network of intercellular interactions. Currently recognized
clinical markers such as tumor morphology and genetic signatures neglect the
role of the cellular ecosystem in determining the outcomes of cancer progression
and treatment [50, 98]. By inferring the underlying networks of interactions be-
tween cellular populations in cancer and analyzing their topologies, it could an-
alyze the robustness of tumors to microenvironmental challenges and therapies,
and identify weak points in the ecological interaction network which, when per-
turbed with treatment, might drive the collapse or growth arrest of the cancer
cell population. Such weak points may involve, for example, positive feedback
interactions between cancer cells and protumoral stromal cells.
In addition, it is possible that the mapping of cancer cellular composition
to multicellular phenotype is degenerate, allowing tumors with disparate cel-
lular compositions to exhibit similar large-scale and long-term behavior. If this
degeneracy is found to be relevant to cancer, this could reduce the functional
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complexity of intertumoral heterogeneity, and explain non-cell autonomous re-
sistance of cancer to treatments that deplete or inhibit the activity of certain cell
subpopulations.
5.2.2 From in vivo experiment
Novel experimental methods such as intravital microscopy have allowed for
the direct imaging of fluorescent-tagged cell subpopulations in solid tumors [2].
Using such techniques, experimentalists have been able to observe the in vivo
emergence of collective cancer cell streaming as a result of pro-invasive feed-
back signaling between breast cancer cells and tumor-associated macrophages
through the EGF/CSF-1 paracrine loop [140]. However, such experiments re-
quire keeping the host animal in a stressed and weakened state, and may not be
feasible for more long-term observations.
For shorter time scale phenomena such as collective motion, spinning disk
confocal microscopy can provide real-time live-animal imaging of single cells
[58, 32]. From such videos, correlation functions can be calculated for cell clus-
ters engaged in collective migration. This would open the path to a quanti-
tative and phenomenological model of information transfer between moving
cells. Such a study would be analogous to animal studies [28, 8, 107] where
phenomenological interactions governing collective motion have been inferred
from high-resolution videos of moving groups. Fluorescence correlation spec-
troscopy measurements of the same collective migration events could corrob-
orate phenomenological interactions with molecular mechanisms by recording
the formation and aggregation of E-cadherin complexes [153], through which
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biochemical and mechanical signals are communicated between collectively mi-
grating cells.
Longer time scale population-dynamical experiments could be performed
using conventional mouse model techniques. A recent study [111] observes
clonal interference in a mouse xenograft system. Cell lines of a common genetic
background were divided into sub-lineages each over-expressing a single se-
creted factor, mixed, and transplanted into mice. In perhaps their most striking
result, a subclone over-expressing interlelukin 11 proved capable of driving the
expansion of the bulk tumor while decreasing in frequency, exhibiting what is
defined evolutionarily as altruistic behavior. Studies in fruit flies also observed
tumorigenesis driven by clonal cooperation [163, 121].
The weakness of these existing studies is they rely on synthetic generation
of a panel of cellular subpopulations. Hence, the phenotypic heterogeneity ob-
served is a result of artificial manipulations and not the native selective pres-
sures and noise experienced by cells residing in a nascent tumor in living tissue.
Thus, even when one observes interesting cell population dynamics and tumor
growth patterns resembling those of clinical tumors, these may not prove an
accurate reproduction of either the small-scale mechanisms or the long-term
bulk dynamics of clinical tumors. Indeed, the long-term population dynamics
of [163] and [111] both result in the extinction of the tumor-driving clone, and
presumably the arrest of tumor progression, at which point the salient question
then becomes: how does a tumor exploit either evolution or phenotypic plastic-
ity to adapt when it, e.g., exhausts a source of key cytokines?
For this reason, a more ideal approach may be to initiate tumors natively
using transgenic techniques, or an (ostensibly) clonal xenograft inoculum, then
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observe the development and evolution of the cell population over time. For
such an approach, a useful platform may be the transparent casper zebrafish
model [159]. This model allows non-invasive imaging of fluorescent-tagged
cells as they proliferate and migrate through the host animal. Combined with a
Cre-based lineage tracing technique (a.k.a. ‘zebrabow’) [129], this would enable
descendent lineages of a clonal xenograft inoculum to be tracked through the
full timescale of disease progression. Using this method, it may be possible to
infer Lotka-Volterra population dynamics models of differentially-labeled sub-
clones at primary and metastatic sites.
5.2.3 From in vitro experiment
Ecological and evolutionary experiments have been performed over long
timescales in microbial populations [154, 161]. Such experiments show poten-
tial for translating to in vitro co-culture experiments using cancer cell lines and
possibly stromal cell lines. The problem is that the collective response observed
would be stripped of the context of the selective pressures of the in vivo tu-
mor microenvironment. Over longer time scales, the discrepancy in culture
conditions could have an increasing impact on the relevance of observations.
A biomimetic culture platform could approximate in vivo microenvironmen-
tal conditions [92], but in general more large-scale evolutionary experiments
should probably be left for in vivo settings.
On the other hand, in vitro studies could be useful in probing the emer-
gent dynamics of specific signaling pathways of interest in collectives of cells.
As evidenced in modeling-driven collective motion studies, simple stimuli-
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response mechanisms may nonetheless produce interesting behavior when in-
tegrated across an interconnected network of individuals differentially affected
by spatial positioning and thermodynamic fluctuation. Culture experiments
have yielded results observing collective motion of cells in chick keratocytes
sufficient for parameterizing an SPP model [150]. The SPP model of collective
motion can be regarded as a 1- to 3-dimensional analogue of the Ising model of
ferromagnetism [156]. That is, the 1- to 3-dimensional velocity vector of each
moving individual aligns and becomes correlated with that of other individuals
as a function of their spatial positions and velocities. For experimental systems
of interaction cells in motion, an interaction matrix can be inferred from the
velocity correlations.
This approach can perhaps be further generalized to correlations between
n-dimensional gene expression vectors of individual cells in culture, where for
experiments that will be both relevant and tractable, n is constrained at the lower
bound by the number of relevant signaling molecules in a given paracrine-
coupled regulatory pathway, and at the upper bound by the number of signal-
ing molecules that may be quantified in real-time with multichannel fluorescent
labeling. An elemental example of such an experiment may be found in the
studies of Gregor et al. [143] on cyclic AMP signaling in the social amoeba Dic-
tystelium. Here, the correlated variable is a 1-dimensional vector consisting of
the cytosolic cAMP concentration of each cell.
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